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ABSTRACT
ANALYSIS OF PRE-COATINGS AND THEIR EFFECT ON ENDOTHELIAL CELL
ADHESION IN A TISSUE ENGINEERED BLOOD VESSEL MIMIC
Rachel Gohres
Cardiovascular disease is the leading cause of death in developing countries. Because
thousands of people are affected by this disease, medical device companies are constantly
developing new intravascular devices in attempt to cure or alleviate the symptoms of the disease.
However, before these devices can be brought to market or implanted in to patients, they must
complete three stages of testing to receive FDA approval. These testing stages include: in vitro
testing, in vivo testing, and clinical trials. Currently, there is a large gap between in vitro and in
vivo testing because it is difficult to obtain physiologic information about a device during in vitro
testing. Therefore, to obtain this information, most devices move on to in vivo testing , increasing
the amount of time, money and animal models used during the approval process. In attempt to
overcome this limitation of the approval process, Dr. Kristen Cardinal developed a tissue
engineered blood vessel mimic (BVM) to bridge the gap between in vitro and in vivo testing to
efficiently test intravascular devices. However, before the BVM can be utilized to test
intravascular devices, key limitations must be overcome. The limitation addressed in this thesis is
the lack of endothelial cell adhesion to the PLGA scaffold used in the BVM. In attempt to
overcome this limitation, protein pre-coatings were characterized in 6-well plates and then
implemented in to the BVM to determine if endothelial cell adhesion could be increased.
The aim of this thesis was to analyze and compare the effects of different protein precoatings coatings on endothelial cell adhesion in 6-well plates and the BVM. The first phase of
this thesis sought to characterize the coatings and their effects on cell attachment in a controlled
and efficient setting. Different aspects of coating protocols were developed during this phase
including the optimization of incubation periods and analysis protocols. The second phase of this
iv

thesis included the implementation of the most effective pre-coatings from the 6-well plate
studies (Conditioning Media and ProNectin-F) in to the BVM to determine which coating was
most effective in increasing cell attachment and reducing cell loss after flow exposure. Using
fluorescent staining and image analysis, it was concluded that Conditioning Media was as
effective as ProNectin-F in increasing cell attachment and retention in the BVM. While both
coatings significantly increased the number of cells adhered compared to a non-coated scaffold,
the endothelial lining in the lumen was not 100% confluent. Therefore, other coatings and/or
combinations of coatings can be studied in the future to continue to improve cell attachment in
the BVM system.
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CHAPTER 1: MOTIVATION AND INTRODUCTION
1.1 Motivation
Since their introduction in 1987, stents have significantly improved the outcomes of
percutaneous coronary interventions (PCI) [1]. Not only have stents dramatically reduced the
need for invasive coronary bypass grafting, but they have proven to reduce restenosis post PCI by
up to 40% [2] . Although stents have been one of the most crucial medical breakthroughs in this
century, they are still being constantly re-developed to improve their mechanical properties,
biocompatibility and hemocompatibility [2, 3]. As more advanced designs are introduced, the
need for cost and time efficient methods of testing escalates with the desire to present a successful
design to the market [3]. Currently, in vivo models are the main source of testing and obtaining
data for new stent designs. However the time, money and number of animals used for testing new
stents could be significantly reduced if there were a way to acquire reliable data from a
physiologically relevant in vitro model [3].
Such an in vitro model, in the form of a “blood vessel mimic” (BVM), is based on the
capabilities gained from the creation of tissue engineered vascular grafts, which are used as a
replacement for a diseased vessel in bypass surgeries [3]. By mimicking the properties of these
grafts, a BVM could be applied as a tool for pre-clinical evaluation of the endothelial response to
stents and other intravascular devices [3]. Therefore, the ultimate goal of the BVM is to bridge
the gap between in vitro and in vivo environments to efficiently test new intravascular device
designs [3].
Although the BVM provides many advantages, there are still crucial limitations of the
design that should be addressed. Currently, the BVM scaffold is made of either an expanded
poly(tetrafluoroethylene) [ePTFE] or poly(lactic-co-glycolic acid) [PLGA] scaffold [4]. Although
both of these materials have shown to be biocompatible, the cell adhesion rates are still relatively
low. During BVM assembly, it has been found that the number of cells that adhere to the scaffold
1

during the sodding stage is much less than the number of cells that are applied [unpublished
work]. Also, imaging of scaffolds post sodding has illustrated an in-consistent layer, or
endothelium, on the lumen of the scaffold [5]. Therefore, not only is the sodding phase of the
BVM assembly inefficient, but the lack of the consistent layer of endothelial cells is an obstacle
that needs to be overcome to successfully simulate a native blood vessel lining. Hence, the aim of
this thesis is to implement the use of different protein pre-coatings on synthetic polymer scaffold
materials to optimize cell adhesion and create a consistent endothelium in the lumen of the
scaffold.
The subsequent Introduction serves to provide the necessary background information
from which this thesis was based. It will include an overview of coronary heart disease and
current treatments, specifically tissue engineered blood vessels and the coatings that are currently
used on them to enhance cell adhesion. It will also include the foundation of a successful BVM
construct and its potential role in in vitro device evaluations, concluding with a specific statement
of the objectives of this thesis.

1.2 Cardiovascular Disease
The American Heart Association estimates that 82,600,000, people, or more than 1 in 3
adults, currently have one or more types of cardiovascular disease [6]. Of these 82,600,000
people, it is estimated that 16,300,000 currently have coronary heart disease [6]. Coronary heart
disease is the leading cause of death for men and women in the United States, causing 1 in 6
deaths in 2006 [7]. It was projected that the cost for treating coronary heart disease was 156.4
billion dollars in 2008 [8].
There is a strong correlation between coronary heart disease and atherosclerosis, the
result of plaque buildup in the arteries that vascularize the heart [9] (Figure 1). The buildup of
plaque in these vessels results in reduced blood flow to the heart causing angina, fatigue,
shortness of breath, heart attack, stroke, or even death [10] . Many of the most successful
2

treatments of this disease are device-based and include: bypass grafting, angioplasty, and stenting
[10].

Figure 1: Atherosclerosis is characterized by the buildup of plaque along the inner wall of
the vessel. When the plaque becomes unstable, it can rupture causing thromboembolisms
that can lead to heart attacks, stroke or death.
http://www.newbhc.com/topics/cardiovascular-risk-support/atherosclerosis/

1.3 Treatments for Cardiovascular Disease
The current treatments that are implemented to treat cardiovascular disease include: lifestyle modifications, pharmaceuticals, and medical procedures [10]. All of these options share the
ultimate goal of relieving the patient of their symptoms, slowing or stopping the progression of
the disease or repairing any damaged tissue. The following sections provide a brief introduction
to medical techniques used in coronary bypass surgery, angioplasty and stenting.
1.3.1 Coronary Artery Bypass Surgery
Coronary and peripheral bypass surgeries are performed more than one million times
annually in the seven major industrialized countries [11]. This procedure treats atherosclerosis by
3

providing a graft that allows the bypassing of the diseased area and re-routes blood flow [12]
(Figure 2). Benefits of this procedure include the long term success in preventing restenosis (the
re-narrowing of a coronary artery), low rates of mortality and low rates of revascularization
procedures [13]. However, some major disadvantages are that this procedure is invasive,
expensive, and requires a long recovery period. In most cases, the patients’ own veins or arteries
are the conduits of choice to avoid an unwanted immune response [13]. Unfortunately, a suitable
vessel is not always available or suitable for grafting, in these cases, a synthetic graft is used [14].

Figure 2: Illustration the re-routing of blood flow due to blockage in a coronary artery
bypass surgery
http://dmzwww.metrohealth.org/body.cfm?id=1321
Advantages of synthetic grafts over other options when an autologous vein is unavailable
include low cost, high availability, and the ability to easily alter their mechanical and physical
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properties [15]. Currently, the most commonly used materials for a synthetic graft include
poly(ethylene terephthalate) ]PET] and expanded poly(tetrafluoroethylene) [ePTFE] [16-19].
Both materials have proven to be successful in grafts for large diameter vessels (>6mm),
however, when applied to smaller diameter vessels, thrombosis rates increase dramatically with
the decreased blood flow [19, 20]. The thrombosis that is responsible for the failure of these
grafts is attributed to the lack of an endothelium on the lumen of the graft and a mismatch in
compliance when compared to native vessels [19]. A solution to this problem is the in vitro
endothelialization of the lumen of the scaffolds prior to implantation [21]. This technique has
proven to drastically reduce the rates of thrombosis in synthetic grafts in vivo [21]. However,
these limitations in addition to the invasiveness of coronary artery bypass grafting, cause other
options such as angioplasty to be a more favorable procedure in some cases [22].
1.3.2 Angioplasty and Stenting
Angioplasty treats atherosclerosis by inserting a catheter and inflating a balloon inside the
blocked region of the vessel to push back or break the clot [23] (Figure 3). Balloon angioplasty is
favored because it is a minimally invasive procedure compared to bypass surgery [23]. However,
a major disadvantage is the high rate of restenosis, or the re-narrowing of the vessel wall due to
the formation of scar tissue due to injury form the balloon inflation [24-26].
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Figure 3: Illustrates the insertion of the catheter in to the vessel, followed by balloon
inflation and removal to ultimately re-widen the artery and restore blood flow.
http://www.medicinenet.com/coronary_angioplasty/article.htm
Stenting is a procedure that treats atherosclerosis by deploying a permanent or semipermanent wire mesh tube to open an artery during balloon angioplasty [27] (Figure 4). Unlike
balloon angioplasty, the stent usually remains in the artery to open the lumen and support
continued blood flow and re-endothelialization [27]. This procedure has resulted in much higher
success rates; consequently 80% of all angioplasties are now combined with stenting [28].
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Figure 4: Illustrates the insertion of a catheter that includes a stent mounted on to a
balloon. (A) The balloon is inflated, expanding the stent pushing back the plaque that is
blocking the artery. (B) The balloon and catheter are removed while the stent remains as a
support for the vessel. (C) http://bcsheart.com/services_coronary_stenting.php
As successful as stenting has proven to be in the last 30 years, serious complications still
remain an issue [29-31]. Complications include thrombosis and in-stent restenosis due to vessel
damage during stent expansion. [30, 31] Also, because the stent is meant to be permanent, it gives
rise to the body’s inflammatory response and other reactions that can also ultimately lead to
restenosis [32]. These issues have been addressed with the introduction of drug eluting stents
[33]. These stents serve to prevent restenosis by releasing medications or bioactive agents in to
the blood stream and surrounding tissues [33]. This has been a very promising advancement in
stent technology and is currently being intensely studied and developed [34-36]. With each new
development in bettering the stent design, the importance of intravascular device testing
increases. As previously stated, the high costs and time consuming limitations of in vivo testing
validate the need for a physiologically relevant in vitro testing system.
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Clinically, tissue engineering has been utilized to develop a physiologic blood vessel
graft for bypass patients that do not have a viable graft. These grafts, known as Tissue Engineered
Vascular Grafts (TEVGs), combine autologous cells and a tubular, biocompatible polymer
scaffold to mimic the function of a native blood vessel. However, in addition to functioning as a
clinical therapy, the methods utilized in the construction of a Tissue Engineered Vascular Graft
can be applied to the development of the previously described BVM in vitro testing system.
Therefore, it is important to understand the development and requirements of a Tissue Engineered
Vascular Graft. It is also important to understand the current limitations of Tissue Engineered
Vascular Grafts, for those limitations are shared by the BVM system. Finally, techniques that are
utilized to overcome the limitations of Tissue Engineered Vascular Grafts will be discussed.

1.4 Tissue Engineered Vascular Grafts
The ultimate goal of a Tissue Engineered Vascular Graft (TEVG) is to mimic at least
some aspects of the anatomy and function of the native blood vessel [37]. Through the use of
autologous cells, a TEVG can be implemented as an autologous vascular graft [37]. In order to
appreciate the advancements made in creating TEVGs, it is important to understand the basic
anatomy of a native vessel, the basic requirements that a TEVG must meet, and the limitations of
the TEVG (which are shared by the BVM) that can be improved upon.
1.4.1 Native Vessel Anatomy
The native artery consists of three distinct layers: the tunica intima, tunica media, and
tunica adventia (Figure 5) [38] . The tunica intima is the blood contacting layer that consists of a
consistent layer of endothelial cells that function to prevent thrombosis and is separated from the
tunica media by the internal elastic lamina [38]. The tunica media consists of smooth muscle cells
within a surrounding extra-cellular matrix (ECM) consisting of collagen and elastin [38]. The
tunica media is responsible for constriction and dilation of the vessel [38]. The tunica adventia
mainly consists of fibroblasts and ECM. The purpose of the tunica adventia is to provide
structural integrity to the vessel [38].
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Figure 5: Illustration of the anatomy of a native blood vessel including the tunica intima,
tunica media and tunica adventitia.
http://bme.ccny.cuny.edu/faculty/jtarbell/SMC%20images.htm
A TEVG is created to mimic the native anatomy of a vessel by harvesting endothelial
cells from native vessels or as derivatives of endothelial progenitor cells, which are then seeded
on to the lumen of a scaffold [39-41]. The synthetic scaffold makes up the internal elastic media
separating the tunica intima from the tunica media [41]. In most cases for TEVGs, the scaffold is
able to provide the structural properties of the tunica media and adventia of a native vessel [41].
However, there are cases in which this is taken one step further and vascular smooth muscle cells
are added to the scaffold surface, prior to endothelial cells, creating a true tunica media [41].
1.4.2 Requirements and Limitations of a Tissue Engineered Vessel Graft
To truly mimic the anatomy and basic functionality of a human blood vessel, the TEVG
must have a confluent layer of endothelial cells lining the entire lumen of the scaffold [37]. In
addition to a confluent endothelium, the TEVG must also have adequate mechanical properties in
order to maintain the correct compliance once it is exposed to pulsatile flow [37]. Finally, the
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TEVG must be cost efficient, easy to store, resistant to degradation, resistant to infection and be
able to be constructed in a reasonable amount of time [37].
As promising as the design of a Tissue Engineered Vascular Graft is, there are still some
important limitations that current research is focused on overcoming [39-42]. One important
limitation is surface thrombogenicity of the TEVG due to an inconsistent layer of endothelium in
the lumen of the scaffold [39-42]. The second major limitation of the TEVG design is the
compliance mismatch between the engineered and native vessels [39-43]. This mismatch can
contribute to a hyperplasic response leading to anastomic intimal hyperplasia and eventually
restenosis [42].
1.4.3 Developing Solutions for TEVG Limitations
As stated previously, the construction of a BVM utilizes the similar methods as the
construction of a TEVG. Therefore, the limitations of the TEVG that were described in the
previous section, mainly the lack of cell adhesion, are shared by the BVM. Therefore, to create a
physiologically relevant in vitro model using these methods, this limitation must be overcome.
Enhanced graft patency occurs when the surface is lined with a consistent endothelium,
making it resistant to platelet aggregation [43]. In order to develop a consistent endothelium in
the lumen of the scaffold, a process known as two-stage seeding, or sodding, is currently used
[44-46]. Sodding consists of the extraction of endothelial cells followed by the prolonged culture
(2-3 weeks) to increase the cell numbers [45]. Once the cell count is high enough, the cells are
then seeded on to the polymeric luminal surface [45].
In recent trials, when the sodding of autologous endothelial cells was implemented with
ePTFE scaffolds, up to 70% of the cells were washed away once the graft was exposed to
pulsatile flow [47]. In other cell adhesion studies utilizing ePTFE scaffolds, only 14%-40% of
the applied cells remained adhered to the scaffold after exposure to pulsatile flow [48]. However,
new techniques that involve the engineering of the lumen of the scaffold to improve cell
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attachment and retention have been developed and have proven to be much more successful [21,
48-57]. These techniques include shear stress preconditioning, electrostatic charging, and most
successfully to date, pre-coating with endothelial specific glues [47-56]. Coatings that have been
examined to date include collagen, fibronectin, gelatin, laminin, extra cellular matrix (ECM),
serum, RGD peptide fragments and pre-clotting the grafts with blood and plasma [21, 51-53, 55,
56, 58, 59]. The goal of the use of these coatings is the development of a compliant, selfendothelializing, non-thrombogenic, polymeric available off-the-shelf small diameter
cardiovascular graft [52]. While all of these coatings have proven to increase cell adhesion when
compared to a non-coated scaffold, some of them have much higher relative adhesion rates [48,
50, 52-56, 58-60]. In the following sections the molecular mechanisms of cell adhesion will be
explained in addition to the comparison and analysis of the coatings listed above. These
mechanisms and coatings will also be important when cell retention in the BVM system is
addressed in later sections.
1.4.4 Molecular Mechanisms of Cell Adhesion on Artificial Materials
When cells adhere to an artificial surface there are two possible mechanisms that are
utilized: direct (non-receptor mediated) binding or receptor mediated binding [58]. Direct cell
adhesion is the non-specific interactions between the molecules on the cell membrane and the
functional chemical groups on the polymer [58]. These interactions consist of weak chemical
bonding including: hydrogen bonds, electrostatic interactions, and polar interactions [58]. This
type of cell adhesion lacks the transmission of signals between the extra cellular environment and
the cells to initiate receptor-mediated adhesion or ECM synthesis and deposition [58]. It has been
determined that without these signals, anchorage dependent cells, such as endothelial cells, will
undergo apoptosis after 24-48 hours [61].
In contrast to direct non-receptor mediated cell adhesion, receptor mediated cell adhesion
to a surface is mediated by molecules within the ECM such as fibronectin, collagen or laminin
[58]. When these ECM proteins are adsorbed on a synthetic material surface, the cells bind
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specific amino acid sequences of these proteins via integrin receptors [58]. The minimum
adhesion motif of these molecules includes three amino acids: Arg-Gly-Asp or the RGD sequence
[58].
The actual process of receptor mediated cell adhesion consists of a cascade of four
different partly overlapping events: initial cell attachment, cell spreading, organization of actin
cytoskeleton, and formation of focal adhesions [62]. In the initial attachment step the cell
contacts the surface and some ligand binding occurs that allows the cell to withstand gentle shear
forces [62]. Secondly, the cell body begins to flatten and its plasma membrane spreads over the
surface [62]. Thirdly, actin filaments organize into microfilament bundles, referred to as stress
fibers to aid in adhesion maturation [62]. Finally, integrin receptors are recruited in to
microdomains on the cell membrane forming “focal adhesions” [62]. In these domains the
integrins communicate with structural and signaling molecules to stabilize the cells attachment
and initiate cell proliferation and differentiation as well as inhibit apoptotic pathways [62].
With these mechanisms in mind, many studies have attempted to utilize receptormediated binding to enhance the endothelialization of TEVGs by pre-coating the scaffold
material with various proteins [43-52].
1.4.5 Pre-Coatings Used to Enhance Cell Adhesion in Tissue Engineered Vascular Grafts
The following subsections serve to examine the various coating techniques and
technologies used to enhance endothelial cell attachment on to the surface of the scaffolds used as
vascular bypass grafts. The success of each coating was quantified by calculating the cell loss
after incubation from the initial number of cells seeded using counting techniques such as
electron microscopy or viability assays such as almar blue [43-55].
1.4.5.1 Serum/Serum Enhanced Cell Culture Medium
Serum is a part of blood that is made up of non-clotting proteins, glucose, nutrients,
electrolytes, hormones, antigens, antibodies, and other particles [56, 57, 63-65]. Albumin and γglobulin are the highest concentrated proteins in serum while fibronectin and laminin have a
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much lower concentration in serum [64]. While albumin and γ-globulin are known to inhibit cell
adhesion, the adsorption of fibronectin, laminin on to surfaces has been shown to increase cell
adhesion [64]. Many studies that involved the pre-coating of scaffolds with serum have found a
significantly increased cellular attachment in comparison with non-coated grafts [51, 52,57, 58].
However, when coating a surface with serum, there is a competitive adsorption of proteins that
both inhibit and encourage cell adhesion on to the surface [64]. Therefore, studies have found that
while a serum coating increased cell adhesion when compared to a non-coated surface, it was
inferior to fibronectin, collagen and laminin alone [52-54, 56, 57, 63-65].
1.4.5.2 Laminin
Laminins are major proteins found in the basal lamina of blood vessels[59]. Laminins are
an important and biologically active part of the basal lamina influencing cell differentiation,
migration and adhesion [59]. When laminin is used as a pre-coating, cellular attachment can be
increased by up to three times when compared to a non-coated graft [55, 59, 65]. However, it too
was found to be inferior to other coatings such as fibronectin, collagen and pre-clotting with
blood or plasma. [50, 54,60]
1.4.5.3 Collagen I
Collagen I is the major insoluble protein in the extracellular matrix and connective tissue
[52]. When used as a pre-coating, collagen was found to significantly increase cell attachment
when compared to non-coated grafts, however the increase was not significant when compared to
other fibronectin, laminin or pre-clotting with plasma or blood [52, 53, 66].
1.4.5.4 Gelatin
Gelatin is a translucent, colorless solid substance that is extracted from collagen
containing only the RGD binding site [67, 68]. In studies, it was confirmed that gelatin coatings
increased cell adhesion when compared to controls, and was also shown to be superior to the use
of laminin as a pre-coating [52, 69]. However, gelatin required a much longer incubation period
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for optimal cell attachment (>2 hours as compared to 60 minutes for other coatings) and it was
also found that up to 40% of adhered cells were washed away once exposed to pulsatile flow [67].
1.4.5.5 Pre-Clotting
The use of pre-clotting with the patients’ own blood or plasma is appealing as a precoating to enhance cell adhesion because it is a simplistic surgical alternative that is more time
and cost efficient when compared to chemical coatings [66]. To date, there have been a very
small number of studies analyzing pre-clotting with plasma, however the results of these studies
have been very promising and have shown to significantly increase cell adhesion to ePTFE
scaffolds when compared to non-coated scaffolds [66]. Pre-clotting with blood, however, has
been studied more intensely and has been found to have superior cell attachment rates when
compared to serum and collagen, but inferior attachment rates compared to fibronectin and
laminin [54, 66, 70].
1.4.5.6 Fibronectin
Fibronectin is an extracellular matrix protein that is known to promote cellular
attachment and spreading [54] . Fibronectin is the peptide sequence that has been most
successfully used clinically for improving cellular attachment and retention [53, 54]. In
comparative studies using ePTFE grafts, fibronectin had superior cell adhesion rates when
compared to adhesion rates of collagen, gelatin laminin, albumin and gelatin [52-54, 71].
However, in other studies when fibronectin was used in combination with any of these other
coatings, cell attachment was found to be far superior to fibronectin used as a coating on its own
[52].
1.4.5.7 Extra Cellular Matrix
The use of the extra cellular matrix (ECM) in its entirety, composed of collagen, laminin,
fibronectin, and elastin has been found to have far superior attachment and retention rates than
fibronectin, collagen or laminin used alone [72].
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As previously stated, the most crucial limitation of the tissue engineered blood vessel is
the inability to create a consistent layer of endothelial cells in the lumen of the scaffold during
seeding in order to prevent thrombosis. Therefore, a large amount of research has been dedicated
to engineering the vessel lumen to increase endothelial cell attachment prior to implantation. The
in vitro testing system in the form of a Blood Vessel Mimic shares this limitation of inefficient
cell adhesion and retention. Hence, the use of pre-coatings such as fibronectin, collagen and other
ECM components can be utilized in the BVM system to enhance cell attachment resulting in a
more consistent endothelium creating a more accurate model of the native vessel.

1.5 The Blood Vessel Mimic as an In Vitro Model
The possibility of implementing a TEVG in vitro to examine the response of the intimal
lining of the endothelium to stent implantation was introduced by the work of Kristen Cardinal in
2006 [3]. The use of the in vitro system would provide a more physiological, cost effective, high
throughput and convenient way to assess new stent designs and their interactions with the
endothelium prior to animal testing [3]. This particular study utilized the extraction of human
endothelial cells from adipose tissue that were then sodded on to the lumen of an ePTFE scaffold
[3]. The cells and scaffold were then allowed to grow within a flow bioreactor until a consistent
endothelium was formed [3]. The system consisted of 2 chambers connected by tubing. One
chamber housed the scaffold and cells while the other served as a media reservoir[3]. The tubing
was connected to a peristaltic pump such that the BVM could be exposed to fluid flow (Figure 6)
[3]. The stents were then deployed in the scaffold within the bioreactor and its effects on the
endothelium were observed [3]. The success of this study shows that the possibility of using a
Blood Vessel Mimic as an in vitro testing system is definitely feasible.
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Figure 6: Bioreactor and BVM system configuration first utilized by Cardinal et al. in 2006.
www.ncbi.nlm.nih.gov/pubmed/17518679
This system was further developed by Cardinal et al. to consist of a rectangular vessel
chamber, media reservoir, and a peristaltic pump (Figure 7). This system was then utilized to
evaluate the endothelialization of modified stent designs as compared to bare metal stents. The
success of this study also supports the feasibility of developing an in vitro testing system for
intravascular devices.

Figure 7: Solid model of the BVM system utilized by Cardinal et al. as well as the studies
conducted for this thesis. Includes the rectangular bioreactor chamber, media reservoir and
pump. http://digitalcommons.calpoly.edu/cgi/viewcontent.cgi?article=1085&context=theses
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The biggest advantage of the BVM is that it provides the potential to produce consistent
reliable data for stent implantation in a controlled model such that stent designs can be compared
directly [4]. However, improvements are still being made to this system because there are still
several physiological and mechanical limitations of the system that still need to be overcome.
Under the guidance of Dr. Kristen Cardinal, many lab researchers are working hard to adjust the
original BVM design to better simulate the in vivo conditions of the native blood vessel. Future
designs hope to include the introduction of pulsatile flow [73], incorporation of smooth muscle
cells to mimic the tunica media [5], and finally increasing the efficiency during the sodding stages
of the BVM set-up. This thesis will address the final limitation of the BVM design with the
ultimate goal of optimizing the BVM’s sodding efficiency and creating a consistent endothelium.
Overall, the goal of this thesis is to improve the endothelial lining in the BVM by using
protein pre-coatings to improve cell retention. To accomplish this goal, several specific aims
were pursued. The first aim was to characterize, compare and asses pre-coatings and their effects
on endothelial cell adhesion in six well plates. The second aim was to then utilize pre-coatings in
the BVM system to compare and assess pre-coatings and their effects on endothelial cell adhesion
to a PLGA scaffold. Preceding both of these aims, protocol development was also necessary.
Results from these aims will be provided in the subsequent chapters.
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CHAPTER 2: PROTOCOL DEVELOPMENT FOR 6-WELL PLATE
COATING EXPERIMENTS
As previously stated, pre-coatings have been utilized to modify the lumen of TEVGs to
overcome limited endothelial cell adhesion. Because the BVM system shares this same limitation,
pre-coatings could also be utilized to increase endothelial cell retention. However, before these
coatings could be implemented in a full BVM system, they first needed to be characterized in a
more controlled and efficient setting, in this case, 6-well plates.
One of the noted advantages of the BVM is that it is a cost effective system for testing
stent deployment when compared to animal testing in vivo. Therefore, it is important that the precoatings used in this system also be as cost-effective. Hence, before experiments began, a costanalysis was first performed. Next, to compare the effectiveness of these coatings in increasing
endothelial cell adhesion in 6-well plates, a protocol was developed to consistently quantify the
number of cells adhered to each well.

2.1 Cost-Analysis of Coatings for 6-Well Plate Experiments
In the current BVM system, the polymer scaffold is allowed to incubate in “Conditioning
Media” (serum enhanced cell culture medium) for twenty minutes prior to cell sodding. Also,
during cell culture, HUVEC Media is allowed to incubate on the culture flask surface for thirty
minutes prior to adding cells. For this reason, both of these solutions were examined as precoatings to enhance HUVEC attachment in the BVM in addition to ProNectin-F(engineered
fibronectin protein) from Sigma-Aldrich due to its success in literature. Therefore, cost analysis
was performed for Conditioning Media, HUVEC media and ProNectin-F for 6-well plate
experiments. A summary of the cost analysis can be found in Table 1 and will be explained
below.
2.1.1 Cost Analysis of ProNectin-F in 6-Well Plate Experiments
The ProNectin-F ordered from Sigma-Aldrich is $114.50 for 1 mg of the fibronectin that
is diluted in to 1mL of the provided diluting solution. To coat two wells in the 6-well plate
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coating analysis, 50 μL of ProNectin-F is diluted in 5 mL of HUVEC media (Lonza). The
calculations for the number of 6-well plate experiments that can be performed for each bottle of
ProNectin-F are as follows:

= 20 6-well plate experiments for $114.50

A bottle of HUVEC media contains 500mL of volume, and 5mL are required for diluting the
ProNectin-F in each 6-well plate experiment. Therefore, for twenty 6-well plate experiments (2wells coated in each experiment) with 5mL of HUVEC media will constitute of one fifth of the
total volume (100mL). The cost to complete twenty 6-well plate experiments with ProNectin-F
diluted in HUVEC media is calculated below:
(

)((

) ) = $24.40

= $138.90 for 20 setups
2.1.2 Cost Analysis of Conditioning Media in 6-Well Plate Experiments
For the six well plate coating experiments, 1.5 mL of Conditioning Media was required to
coat one well. Conditioning Media requires both fetal bovine serum (FBS) and base media
(M199), ordered from Sigma-Aldrich. The calculations for twenty 6-well plate set-ups for
Conditioning Media are as follows:
500 mL of FBS = $124.50
One bottle of Conditioning Media contains 83mL of FBS
$124.50(83/500) = $20.67
One bottle of M199 = $8.24
Cost of one bottle of Conditioning Media: $20.67+$8.24 = $28.91
For twenty setups, 30mL of the 500mL bottle is consumed, therefore the cost to complete twenty
6-well plate experiments with Conditioning Media is:
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($28.91)(0.06) = $1.73
2.1.3 Cost Analysis of HUVEC Media Alone for 6-Well Plate Experiments
To coat two wells with HUVEC media, 3.0mL of media is required. The calculations of
the cost to complete twenty 6-well plate experiments with HUVEC media are as follows.
500mL of HUVEC Media= $122.
20 experiments require 60mL of the 500mL bottle =12%.
($122)(0.12) = $14.64
Table 1: Summary of the Cost-Analysis for Pro-Nectin F, Conditioning Media and HUVEC
media for 6-Well plate experiments
Coating
ProNectin-F
diluted
HUVEC media
Conditioning Media
HUVEC Media

Volume Required for 20
Setups
in 100 mL

Cost for 20 Setups
$138.90

30 mL

$1.73

60 mL

$14.64

It is obvious that of these three pre-coatings, Conditioning Media is the most cost efficient
option. However, the efficiency of the coating in enhancing cell attachment in a BVM is also an
important property of the coating. There are many variables in the BVM system that can affect
cell adhesion in addition to the coatings, such as the cell sodding procedure and fluid flow
exposure. Therefore, in order to accurately evaluate the efficiency of each coating for HUVEC
attachment, a protocol was developed for to compare them in 6-well plates.

2.2 Protocol Development for the Analysis of Pre Coatings in 6-Well Plate
Experiments
In order to determine the ability of Pro-Nectin F, Conditioning Media, and HUVEC
media to promote cell adhesion in a 6-well plate experiment, it was necessary to establish a
protocol that could be utilized for each experiment to determine the number of cells that adhered
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to each well. In the following sub-sections, a summary of the protocols that were used will be
provided along with a discussion of what was successful and what was altered in subsequent
protocols. The full protocols can be found in Appendix A. A summary of the conclusions that
were drawn from each protocol can be found in Table 2.
2.2.1 Methods: Protocol #1
2.2.1.1 Coating Preparation
HUVEC Media was prepared following the Lonza Bullet Kit instructions (Lonza: CC3162). ProNectin-F (Sigma: F5022) was prepared by diluting 50μL of the stock ProNectin-F
solution into 5mL of HUVEC media. Conditioning Media was prepared by combining 83mL of
FBS (Sigma: F4135) with 500mL of M199 (Lonza: 181474).
2.2.1.2 Cell Selection and Culture
Human umbilical vein endothelial cells (HUVECs) were purchased from Lonza (Lonza:
CC-2517) and stored in vials in a liquid nitrogen dewar. Vials of P6 HUVECs were thawed and
cultured according to standard practices. Cells were maintained at 37℃ and 5% CO2 for the
culture and expansion process.
2.2.1.3 Preparation of 6-Well Plates
Once each pre-coating was prepared, 1.5mL of each coating was added to previously
specified and labeled wells in three VWR 6-well plates and allowed to incubate for 20 minutes
(Figure 8). The incubation occurred at 37℃ and 5% CO2. During this incubation, HUVECs were
detached from a 225 mL cell culture flask using trypsin. After 20 minutes of incubation, the
coatings were aspirated and 1mL of HUVEC media was added to each well along with 1.5mL of
the suspended cell solution from the culture flask. The wells, now containing cells, were then
incubated for 15 minutes except for wells 6, 12 and 18 that were only allowed to incubate for 5
minutes (full protocol in Appendix A.1).
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2.2.1.4 Quantifying the Number of Cells Adhered to Wells
Cell counts were obtained using a Nexcelom Bioscience Cellometer (Figure 9). The
Nexcelom Bioscience Cellometer utilizes bright field imaging and pattern-recognition software to
quickly and accurately identify and count individual cells suspended in a solution[74]. Cell count,
concentration, diameter, and % viability are automatically calculated and reported [74]. An initial
cell count prior to adding the cells to the 6-well plates was obtained from the Nexcelom
Bioscience Cellometer. The initial number of cells counted was 6.3x106. This value was then
divided by 18 to obtain an initial cell count per well (see sample calculation below). After the
allotted incubation time, the solution was removed from each well in to individual petri dishes.
This solution contained the cells from each well that did not adhere to the surface. Therefore, to
calculate the number of cells that did adhere to the wells, this number would be subtracted from
the initial number of cells that were assumed to be in each well (see sample calculation below).
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Well Legend:
1, 7, 13: No Coating
2, 8, 14: Conditioning Media
3, 9, 15: HUVEC Media
4, 10, 16: ProNectin- F+ HUVEC Media
5, 11, 17: ProNectin-[74] F+PBS
6, 12, 18: HUVEC Media with 5 Minute Cell Incubation

Figure 8: Diagram of the 6-well plates and applied coatings used in Protocol #1.

Figure 9: Illustration of the Nexcelom Cellometer and the Cell Counting Process. A:
Nexcelom Cellometer. B: Process Utilized to Count Cells C: Example of Nexcelom
Cellometer Cell Tracing and Counting
2.2.2 Discussion: Protocol #1
During this experiment, the presence of three 6-Well plates in the tissue culture hood
simultaneously created stress for both aseptic space in the hood as well as time. In order to
accurately determine the number of cells that did not adhere, the solution had to be removed from
the wells quickly to avoid more cells adhering to the surface post-incubation. This was difficult to
manage with 18 different wells. Also, once all of the media had been removed from the wells in
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to individual petri dishes, many of the cells had adhered to the bottom of the petri dishes during
the counting stages, resulting in inaccurate cell counts. Also, due to the long incubation period
(15 minutes), there were few cells in the non-adhered solution, resulting in the inability to obtain
automated counts.
It was determined that in future protocol development experiments only one 6-well plate
would be used and that the incubation period would be reduced to five minutes to increase the
number of cells in the non-adhered solution. These changes were made in attempt to reduce time
and space constraints as well as provide enough cells to produce automated cell counts. Finally, it
was determined that the ProNectin-F would be more effective when diluted in HUVEC media as
compared to PBS. Therefore, in future protocols ProNectin-F was diluted in HUVEC media.
2.2.3 Methods: Protocol #2
2.2.3.1 Coating Preparation and Cell Culture
Completed using methods described in Protocol #1 (Section 2.2.1.2).
2.2.3.2 Preparation of 6-Well Plates
Because only one 6-well plate was being coated for this protocol, a confluent 75mL cell
culture flask was used instead of a 225mL cell culture flask. Like Protocol #1, 1.5 mL of each
coating was applied to the specified wells and allowed to incubate for 20 minutes. An initial cell
count was obtained from the T-75 culture flask like Protocol #1; however this number was
divided by six instead of eighteen to quantify the number of cells being added to each well. Each
well was assigned and coating and labeled (Figure 10). As previously stated, this protocol
reduced the incubation time for the cells in the coated wells from twenty minutes to five minutes
(full protocol in Appendix A.2).
2.2.3.3 Quantifying the Number of Cells Adhered to Wells
Completed using the same methods described in Protocol #1 (Section 2.2.1.4).
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Well Legend:
1: No Coating
2: Conditioning Media
3: HUVEC Media
4: Pro-Nectin F+ HUVEC Media
5: Pro-Nectin F+HUVEC Media
6: HUVEC Media

Figure 10: Diagram of the 6-well plate and applied coatings used in Protocol #2.
2.2.4 Discussion: Protocol #2
Reducing the number of 6-well plates used in the protocol development experiments from
three to one increased to amount of aseptic space and eliminated the time constraint during the
removal of non-adhered cells post incubation. However, it was still difficult to obtain automated
counts for the non-adhered cells. It was determined that this was because the Nexcelom
Bioscience Cellometer had a minimal threshold ratio of cells to solution. This concentration had
to be met in order to automatically trace and calculate the number of cells present in a solution.
Therefore, it was decided that more cells needed to be present in each well to increase the
concentration. It was also concluded that it would be more efficient to directly count the adhered
cells rather than the non-adhered cells in each well.
2.2.5 Methods: Protocol #3
2.2.5.1 Coating Preparation and Cell Culture
The coatings and cells were prepared using the methods described in Protocol #1 (Section
2.2.1.2).
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2.2.5.2 Preparation of 6-Well Plates
Completed using methods described in Protocol #2, with the exception of a confluent
225mL cell culture flask of HUVECs instead of a 75mL cell culture flask. Each well was
assigned a coating and labeled (Figure 11).
2.2.5.2 Quantifying the Number of Cells Adhered to Wells
After the cells were incubated in the coated wells, the solution containing the nonadhered cells was discarded and 1mL of trypsin was added to each well to detach the adhered
cells from the wells. Once the cells were detached, the trypsin was deactivated with 2 mL of
HUVEC media and the solution containing the adhered cells was moved in to individual 15mL
conicals so that the number of adhered cells in each well could be counted (full protocol in
Appendix A.3).

Well Legend:
1: No Coating
2: Conditioning Media
3: HUVEC Media
4: Pro-Nectin F+ HUVEC Media
5: Pro-Nectin F+PBS
6: HUVEC Media

Figure 11: Diagram of the 6-well plate and applied coatings used in Protocol #3.
2.2.6 Discussion: Protocol #3
Although the number of cells added to the wells was increased, the threshold cell-tosolution ratio still was not met and automated cell counts were not obtained. Therefore, in order
to further increase this ratio it was determined that the amount of solution that the cells were
suspended in had to be decreased.
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2.2.7 Methods: Protocol #4
2.2.7.1 Coating Preparation and Cell Culture
The coatings and cells were prepared using the methods described in Protocol #1
(Sections 2.2.1.1-2.2.1.2).
2.2.7.1 Preparation of 6-Well Plates
The 6-well plates were prepared using the methods described in Protocol #3. Each well
was assigned a coating and labeled (Figure 12)
2.2.7.2 Quantifying the Number of Cells Adhered to Wells
Cell counts were performed for both the adhered and non-adhered cells to ensure that all
of the cells counted initially were accounted for. After the incubation period, the non-adhered cell
solution from each well was moved to a second 6-well plate and was submitted for cell-counting.
Also, to increase to cell-to-solution ratio in attempt to meet the threshold for the Nexcelom
Cellometer, the solution that the cells were suspended in was decreased to 0.5mL. This solution
was then submitted for automated cell counts (full protocol in Appendix A.4).

Well Legend:
1: No Coating
2: Conditioning Media
3: HUVEC Media
4: Pro-Nectin F+ HUVEC Media
5: Pro-Nectin F+PBS
6: HUVEC Media

Figure 12: Diagram of the 6-well plate and applied coatings used in Protocol #4.
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2.2.8 Discussion: Protocol #4
Using Protocol #4, cell counts were successfully obtained for both adhered and nonadhered cells in each well because the threshold for the cell counter was met by reducing the
volume of solution that the cells were suspended in.
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Table 2: Summary of the process in establishing a protocol for the analysis of 6-well plate
experiments
Protocol

What Was Changed

What Worked

What Did Not Work

Protocol #1

N/A

1. All of the coatings
were effective and
resulted in adhered cells
to the wells

1. Three six well plates
was too chaotic for a new,
un-established protocol.
2. Incubation time for
cells in a 6 well plate was
too long. Too many cells
adhered and there were
not enough to meet
threshold for cell- counter
in the non-adhered
cell/media solution

Protocol #2

1. Only one six well plate
was used.
2. Cell incubation time in
wells was reduced from
20 minutes to 5 minutes.
3. ProNectin-F was only
diluted in HUVEC media,
not PBS.

1.Only using one six well
plate to analyze coatings
was much more
manageable
2. Five minute cell
incubation time was
enough to allow cells to
adhere, but also enough to
remain non-adhered to
attempt to meet threshold
for cell counter

1.Too much time for
counting non-adhered
cells, cells began to
adhere to surface of the
Petri dish
2.Could not get counts of
non-adhered cells for all
of the wells

Protocol #3

1. Decided to obtain
counts for adhered cells
instead of non-adhered
cells.
2. Began with more cells,
used a T-225 culture flask
instead of T-75
3. Detached cells from
wells using trypsin and
deactivated with HUVEC
media prior to counting.
1. Decided to obtain
counts for both adhere
and non-adhered cells.
2. After cells were
removed from wells, the
solution was centrifuged
and excess media was
removed such that the
adhered cells were
suspended in ~0.5mL of
solution

1. Detachment of cells
from individual wells
using trypsin, confirmed
by cell counter and scope
that the cells were
removed efficiently from
the wells.

1. Still unable to get
counts for adhered cells.

1. Counts were
successfully obtained for
both adhered and nonadhered cells.

1. Nothing, this protocol
was efficient and
successful

Protocol #4
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2.2.9 Discussion of Protocol Development
After implementing four different protocols, it was determined that Protocol #4 was an
efficient and accurate procedure for examining the effects of a coating on cell attachment in a 6well plate. The analysis steps utilized in Protocol #4 were implemented in to all future protocols
that served to analyze coating efficiency concerning cell adhesion in a 6-well plate.
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CHAPTER 3: INCUBATION TIME AND COMPARISON STUDIES
OF PRE-COATINGS IN 6-WELL PLATES
In the protocol development stages, the amount of time that the 6-well plates incubated
both with and without cells was based on values seen in literature [50, 52, 54, 59]. However,
multiple incubation periods were used for both coating and cell incubation times in different
studies [50, 52, 54, 59]. The coating incubation time is defined as the amount of time that the precoating is allowed to incubate on the 6-well plate prior to adding cells. The cell incubation time is
defined as the amount of time that the cells are allowed to incubate on the coated surface prior to
analysis. However, it was not stated how these different incubation times effected the number of
endothelial cells that attached to the coated surfaces. Determining how the coating and cell
incubation times affect cell adhesion allowed for the optimization of coating protocols to
maximize cell adhesion.
In pre-coating cell adhesion studies, it was repeatedly found that the use of ProNectin-F
as a pre-coating to enhance cell adhesion was more successful than other coatings that were
implemented [52-55, 64, 67]. However, this coating is also a very expensive alternative and
would need to significantly outperform Conditioning Media (the current BVM coatings) in
increasing endothelial cell adhesion to be considered for use in the BVM system. As previously
stated, these studies were first performed in 6-well plates to avoid factors within the BVM system
that may affect cell adhesion in addition to the pre-coatings.

3.1 Analysis of the Effects of Coating and Cell Incubation Times on
Endothelial Cell Adhesion
As previously stated, two different incubation times are required in the pre-coating
protocol: coating incubation and cell incubation. This study sought to determine how varying
these incubation periods affected the number of endothelial cells adhered to the coated surfaces.
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3.1.1 Methods
3.1.1.1 Coating Preparation and Cell Culture
Conditioning Media was prepared using the same methods described in Protocol
Development sections. Culture of P6 HUVECs, thawing and expansion was also completed using
the same methods described in the Protocol Development sections (Section 2.2.1.2).
3.1.1.2 Preparation of 6-Well Plates
Because this experiment sought to only analyze the effects of different incubation times
on cell adhesion, all wells were coated with 1.5mL Conditioning Media. In this experiment, four
6-well plates were utilized and each well was assigned a coating incubation time of 10, 20 or 30
minutes and a cell incubation time of 2, 5 or 8 minutes. One 6-well plate was used for the
staggering of varying coating incubation times. Conditioning Media was added to well 3 and 6
first and allowed to incubate for 10 minutes at 37℃, 5% CO2. After ten minutes, Conditioning
Media was added to wells 2,5, and 7-12 and placed back in the incubator for 10 more minutes.
Conditioning Media was then added to wells 1 and 4 and the plate was placed back in the
incubator for the final 10 minute incubation. Wells 7-12 were also incubated during the final ten
minutes (20 minute total incubation time). The wells that varied in cell incubation times were in 3
separate 6-well plates. This was done because after the cell incubation time was completed, the
adhered and non-adhered cells were removed from the wells. This process requires the 6-well
plate to be out of the incubator for 5-7 minutes, and would result in inaccurate cell incubation
times if they were all on the same plate. By utilizing three 6-well plates, the longer cell incubation
periods can continue will cells are being removed from the wells assigned shorter incubation
periods. The assignments of the wells can be found in Figure 13. The full protocol used for this
experiment can be found in Appendix A.5.
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1. 10 min coating incubation. 5 min cell incubation
2. 20 min coating incubation. 5 min cell incubation
3. 30 min coating incubation. 5 min cell incubation
4. 10 min coating incubation. 5 min cell incubation
5. 20 min coating incubation. 5 min cell incubation
6. 30 min coating incubation. 5 min cell incubation
7. 20 min coating incubation. 2 min cell incubation
8. 20 min coating incubation. 2 min cell incubation
9. 20 min coating incubation. 5 min cell incubation
10.20 min coating incubation. 5 min cell incubation
11.20 min coating incubation. 8 min cell incubation
12.20 min coating incubation. 8 min cell incubation

Figure 13: Well assignments for the assessment of the effects of coating and cell incubation time
on cell adhesion
3.1.1.3 Quantifying the Number of Cells Adhered to Wells
The methods described in Protocol #4 of Protocol Development were utilized in this
study to obtain cell counts for adhered and non-adhered cells in each well (Section 2.2.7.2).
3.1.2 Results
As illustrated in Figure 14, the results of this experiment indicated that varying the
amount of time that the coated surfaces are incubated prior to adding cells did not affect the
number of cells that adhered to the coated surface. However, an increasing trend was observed for
the number of cells that adhered to the coated surface as the cell incubation time increased.
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Figure 14: Results of incubation time experiment. Cells adhered after varying cell and coating
incubation periods. Represented as a percentage of the initial number of cells counted in the
well.
3.1.3 Discussion
As previously stated, it was observed that varying the coating incubation period did not
result in a large variation in cell adhesion. Therefore, it was concluded that this incubation period
did not have a significant effect on endothelial cell adhesion to coated surfaces and would be kept
constant in future experiments. However, in contrast to coating incubation, increasing cell
incubation times did result an increasing trend in percent cells adhered. Hence, it was concluded
that the cell incubation period will have an effect on endothelial cell adhesion and would be
considered during the BVM coating protocol development stages (Chapter 4).

3.2 Comparison of ProNectin-F and Conditioning Media as a Pre-Coating in
6-Well Plates
In literature, when ProNectin-F was used as a pre-coating on a TEVG, it was found that
maximal cell adhesion was obtained when the cells were allowed in incubate on surface for 60-90
minutes [50, 52, 54, 55, 64, 67]. To determine how the successful, yet expensive, ProNectin-F
pre-coating compared to Conditioning Media in increasing cell adhesion, a comparison study was
designed. This study served to evaluate the efficacy of ProNectin-F and Conditioning Media
compared to a non-coated surface in terms of endothelial cell adhesion after 60 and 90 minute cell
incubation periods.
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3.2.1 Methods
3.2.1.1 Coating Preparation and Cell Culture
Conditioning Media and ProNectin-F were prepared using the same methods described in
Protocol Development sections (Section 2.2.1.1). Culture of P6 HUVECs, thawing and expansion
was also completed using the same methods described in the Protocol Development sections
(Section 2.2.1.2)
3.2.1.2 Preparation of 6-Well Plates
Each coating (or non-coated) was assigned to three wells for each time point. The well
assignments can be found in Figure 14. All 18 wells were incubated with the assigned coating for
20 minutes prior to adding cells. The endothelial cells were then added to each well and were
incubated for 60 or 90 minutes. The full protocol used in this experiment can be found in
Appendix A.6.
3.2.1.3 Quantifying the Number of Cells Adhered to Wells
The same methods described in Protocol #4 of Protocol Development were utilized to
obtain cell counts for adhered and non-adhered cells in each well (Section 2.2.7.2).
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1: Conditioning Media: 60 Minute Incubation
2: Conditioning Media: 60 Minute Incubation
3: Conditioning Media: 60 Minute Incubation
4: ProNectin F: 60 Minute Incubation
5: ProNectin F: 60 Minute Incubation
6: ProNectin F: 60 Minute Incubation
7: Conditioning Media: 90 Minute Incubation
8: Conditioning Media: 90 Minute Incubation
9: Conditioning Media: 90 Minute Incubation
10: ProNectin F: 90 Minute Incubation
11: ProNectin F: 90 Minute Incubation
12: ProNectin F: 90 Minute Incubation
13: No Coating: 60 Minute Incubation
14: No Coating: 60 Minute Incubation
15: No Coating: 60 Minute Incubation
16: No Coating: 90 Minute Incubation
17: No Coating: 90 Minute Incubation
18: No Coating: 90 Minute Incubation

Figure 15: Coating and incubation well assignment for the ProNectin F Conditioning Media comparison experiment

3.2.2 Results
As illustrated in Figure 16, the use of Conditioning Media and ProNectin-F as precoatings significantly increased the number of cells that adhered to the 6-well plates when
compared to a non-coated control. The results from the experiment also indicate that significantly
more cells adhere after 90 minutes of cell incubation when compared to 60 minutes of incubation
regardless of the coating. Lastly, the results of this study indicate that there was no significant
difference between the number of cells that adhered when Conditioning Media or ProNectin-F
were used as a pre-coating.
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Percent Cells Adhered to Wells Pre-Coated with Conditioning
Media and ProNectin-F after 60 and 90 Minute Incubation
*
Periods
Percent Cells Adhered in Well

1.2
1
0.8

**
*

**
*
*

**

0.6

60 Minutes

0.4

90 Minutes

0.2
0
No Coating

Conditioning Media

ProNectin-F

Figure 16: Percent of total cells adhered to wells pre-coated with Conditioning Media and
ProNectin-F after 60 and 90 minute incubation periods. * p<0.05 for percent cells adhered
after 90 minutes of incubation compared to 60 minutes of incubation for individual coatings
including non-coated. ** p<0.05 for percent cells adhered to a coated surface compared to
non-coated control after 90 minute incubation period.
3.2.3 Discussion
The results from this experiment supported the hypothesis that the use of pre-coatings
would significantly increase the number of cells that adhered to the surface of the 6-well plates
when compared to wells that did not have a coating. In addition, there was not a significant
difference in the number of cells that adhered to the Conditioning Media coated surfaces and the
ProNectin-F coated surfaces. This was a beneficial finding for the BVM protocol because it
indicated that the coating that is currently implemented in constructing a BVM is as effective as
the much more expensive ProNectin-F alternative.

3.3 Discussion of 6-Well Plate Coating Experiments
The 6-well plate coating experiments resulted in two main conclusions: the coating
incubation time does not significantly affect the number of cells adhered to a coated surface and
that there was not a significant difference in the number of cells that adhered to the Conditioning
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Media coated surfaces and the ProNectin-F coated surfaces. However, it is important to note that
6-well plates are not composed of the same material as a BVM scaffold and are not exposed to
fluid flow or shear forces.
In literature studies in which ProNectin-F was found to be a very successful pre-coating,
the cells were exposed to flow either in a bioreactor or the human circulatory system [53, 54]. In
these studies it was concluded that the cells were able to create a stronger attachment to the
materials that were coated with ProNectin-F when compared to other materials because
significantly less cells “washed off” the material once it was exposed to flow [53, 54]. Hence, it is
possible that Conditioning Media and ProNectin-F cause a similar number of cells to adhere to a
BVM scaffold initially, prior to flow exposure, as seen in the 6-well plate experiments; but that
once the cells are exposed to flow, one coating would prove to be more effective than the other.
Therefore, to further characterize these pre-coatings and their effects on endothelial cell adhesion,
the coatings were implemented into BVM system. To accomplish this, modifications to the
protocol that was developed in Chapter 2 were first necessary to consistently analyze the
efficiency of these coatings on PLGA scaffolds. Protocol development will be presented in the
next chapter, with BVM experiments presented in Chapter 5.
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CHAPTER 4: PROTOCOL DEVELOPMENT FOR THE ANALYSIS
OF PRE-COATINGS IN A BVM
The efficiency of the sodding stages during BVM construction had never been quantified
in this laboratory. However, it has been noted in previous work in this laboratory that a significant
amount of cells are lost from sodding stages to later time-points of 3-7 days of flow exposure [5,
73, 75]. However, before developing a protocol to implement and compare pre-coatings in a
BVM, it was important to perform another cost analysis of the coatings for these studies. In this
chapter, a cost analysis was performed for Conditioning Media and ProNectin-F for two BVM
studies and a protocol was developed using similar analysis steps from the 6-well plate
experiments. PLGA was chosen as the scaffold material for the coating experiments because
PLGA is currently the more common scaffold utilized for BVMs in the laboratory, and it can be
electrospun in the laboratory, resulting in more availability, lower costs and no dependency on
ePTFE suppliers [76].

4.1 Cost Analysis for Coatings in the BVM System
After the 6-well plate experiments, it was concluded that Conditioning Media and
Pronectin-F were more efficient than HUVEC media in encouraging endothelial cell adhesion to
a synthetic surface. Therefore, these pre-coatings were chosen to be utilized in the BVM system
to determine which coating is more efficient in increasing endothelial cell adhesion in a BVM. As
previously stated, one of the benefits of utilizing the BVM as an in vitro testing platform is that it
is cost efficient when compared to in vivo testing. Hence, the cost of the coatings must be
considered when determining which is the best coating for the BVM system. A summary of the
analysis can be found in Table 8 and will be explained below.
4.1.1 Cost Analysis of ProNectin-F in BVM Setups
As stated in Section 2.1.1, ProNectin-F is $114.50 for 1 mg that is diluted in 1mL of the
diluting solution. A total of 450μL of ProNectin-F diluted in 45 mL of HUVEC media is required
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for the BVM setup (35mL for the media reservoir and 10mL for priming the scaffold). The
calculations for the cost of using ProNectin-F as a pre-coating in the BVM system are as follows:

(

)((

) ) = $21.96

= $166.46 for 2 BVM setups

4.1.2 Cost Analysis of Conditioning Media in BVM Setups
As stated in Section 2.1.2, the cost to make one 500mL bottle of Conditioning Media is
$28.91. A total of 45mL is required for the BVM setup (35mL for the media reservoir and 10mL
for priming the scaffold). The calculations for the cost of using Conditioning Media as a precoating in the BVM system are as follows:
($28.91per bottle of Conditioning Media)(0.09) = $2.60 per BVM setup
Table 3: Summary of the cost-analysis for Pro-Nectin F and Conditioning Media for a BVM
setup
Coating
ProNectin-F diluted in
HUVEC media
Conditioning Media

Volume Required for 1
BVM Setup
45 mL

Cost per Setup
$83.23

45 mL

$2.60

Again, it is obvious that Conditioning Media is the most cost-efficient pre-coating for the
BVM system. However, as previously stated, the coatings effectiveness in increasing endothelial
cell adhesion in the BVM is also a crucial property of the coating. Therefore, to determine which
coating was more suitable for the BVM system, a protocol had to be developed such that the
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efficiency of Conditioning Media and ProNectin-F in increasing cell adhesion in a BVM could be
compared to one another.

4.2 Protocol Development for Analysis of Pre-Coatings in a BVM
Like the 6-well plate protocol development stages, a protocol had to be developed to
compare the effects of different pre-coatings on endothelial cell adhesion in a BVM. In literature,
pre-coatings were evaluated in TEVGs by comparing % adhered and % non-adhered values for
each coating [44, 52, 54]. Therefore, an attempt was made to develop a protocol to quantify these
values in the BVM setup. During the BVM protocol development stages, only Conditioning
Media was used as a pre-coating due to the high cost of ProNectin-F. The full protocol used for
this setup can be found in Appendix B.1.
4.2.1 Methods
4.2.1.1 Cell Selection and Cell Culture
The methods described in the 6-well plate experiments in Chapter 2 were utilized to
select, and thaw P4 HUVECs (Section 2.2.1.2). The HUVECs were expanded to P6 and were
used once the flasks were 80% confluent.
4.2.1.2 Preparation of PLGA Scaffolds
One 15 wt% PLGA scaffold was electrospun by another student using previously
developed methods. Two 4cm sections were cut from the scaffold and sutured to luer lock fittings
on each side with a silk suture. The scaffolds were then sterilized in 70% EtOH for 30 minutes.
After sterilization, each scaffold was syringe-rinsed with PBS followed by a syringe-prime with
Conditioning Media. To accomplish this, the PBS and media were flushed through the lumen of
the scaffold to remove the air. The luminal outlet was then closed and the PBS and media were
forced out through the pores of the scaffold. Both of these rinsing processes were the repeated
with Conditioning Media to prime the scaffolds.
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4.2.1.3 Preparation of Bioreactors
Bioreactor media and Conditioning Media were warmed to 37℃ in a water bath. Using
aseptic technique, bioreactor media was added to each bioreactor such that the scaffolds would be
completely submerged when inserted. The media reservoirs were also filled with Conditioning
Media (Figure 17). The rinsed and primed scaffolds were then inserted in to the bioreactors. The
bioreactors with the scaffolds and media reservoirs filled with Conditioning Media were then
placed in a large incubator and hooked up to a peristaltic pump (Figure 17).

BVM hooked up
to peristaltic
pump

Figure 17: Illustration of PLGA scaffolds inserted in to the BVM. The BVM and media
reservoirs were then hooked up to a peristaltic pump in a large incubator.
4.2.1.4 Dynamic Conditioning
Each bioreactor was primed using the peristaltic pump to remove all air from the systems.
After priming, transluminal flow was restricted, forcing Conditioning Media through the pores of
the scaffold at 150rpm. The dynamic conditioning of the scaffolds was continued for 20 minutes.
4.2.1.5 Pressure Sodding of HUVECs
At the end of the dynamic conditioning process, each bioreactor was removed from the
incubator and placed back in the laminar flow hood for cell sodding. HUVECs were harvested
from VWR 225mL cell culture flasks with 1X trypsin and an initial cell count was obtained using
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the Bioscience Nexcelom Cellometer. The cells were centrifuged for 4 minutes and re-suspended
in 6mL of HUVEC media. The cell solution was moved into a trough and inserted in to the BVM
via pressure sodding. Each scaffold was pressure sodded with approximately 3 million cells per
scaffold using sterile techniques. Pressure sodding consists of restricting transluminal flow such
that when cell solution is syringed in to the system, the cells are forced in to the wall of the
scaffold, attaching to and covering the luminal surface. The cells were then chased with 3mL of
HUVEC media using the syringe. The bioreactors were placed back in to the large incubator and
hooked up to the peristaltic pump. The pressure sodding was continued in the incubator for one
hour at 10rpm transmural flow. The bioreactors were then incubated statically for one hour to
allow for proper cell adhesion. The incubator was maintained at 37℃ and 5% CO2.
4.2.1.6 Harvesting of Scaffolds and Non-Adhered Cells from Bioreactors
Scaffold harvesting was conducted by removing each BVM from the large incubator. All
valves were closed on the bioreactor and 15 ml VWR conical tubes were labeled appropriately
and filled with approximately 10-12 ml of histochoice fixative. Each HUVEC sodded PLGA
scaffold was removed from the chamber and barb fittings using a surgical scalpel. Each scaffold
was then transferred to one of the prepared histochoice filled tubes.
It was assumed that the cells that had not adhered to the luminal surface of the scaffolds
would be found in the bioreactor media or media reservoirs. To quantify the number of nonadhered cells, the media from these locations was centrifuged for 4 minutes and re-suspended in 1
mL of HUVEC media. Samples from this volume were then submitted to the Nexcelom
Cellometer to count the number of non-adhered cells.
4.2.1.7 Fluorescent Microscopy
To quantify the number of cells adhered to the luminal surface of the scaffold, a Bisbenzimide (BBI, Em λ 460nm) stain was used (Appendix C.1). To maintain the integrity of this
light sensitive stain, two 15mL VWR conicals were wrapped in aluminum foil from base to cap to
minimize light exposure. Ten mL of Mili-Q (non-sterile) was added to each conical tube. Ten μL
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of BBI was added to the Mili-Q in the covered tubes and shaken. The fixed scaffolds were then
removed from the histochoice and cut longitudinally to expose the lumen for staining. Each half
of the scaffolds was then placed in the covered conicals for a minimum of 20 minutes. Images of
each scaffold were then obtained using an Olympus fluorescent microscope.
4.2.1.8 Image Analysis
The image analysis program ImageJ was utilized to quantify the number of cells adhered
to the lumen of each scaffold. Four images of each scaffold half were obtained at 10X using the
Olympus fluorescent microscope and camera system, resulting in eight images per scaffold.
Using ImageJ, four equal sized boxes were placed throughout each image. Using the Cell Counter
plug-in in ImageJ, the number of cells in each box was counted by manually clicking on each cell
(Figure 18). The number of cells in the four boxes was averaged to obtain an average cell density
in that image (Figure 19). This was repeated for all eight images for each scaffold. Those eight
values were then averaged to obtain an average cell density per scaffold.
The counts obtained in ImageJ have a unit of cells/pixels 2. To convert this density to
cells/ cm2 a Ranchi Ruling was used. The final cell density of the scaffold was then multiplied by
the surface area of the scaffold to obtain the number of adhered cells.
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Figure 18: Illustration of the BBI image analysis using the Cell Counter in ImageJ. 4 boxes
were drawn throughout the image and each cell was counted by manual clicking

Figure 19: Illustration of image analysis technique. The four squares that had
the most cells in focus were used to count cells for each image.
4.2.2 Results
As seen in Table 3, after one hour static incubation, only 10.68% of the applied cells
were counted from the BBI images using ImageJ. However, combining this result with the
number of non-adhered cells counted in the BVM media, only 17.50% of the applied cells were
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accounted for. Interestingly, the BBI images illustrated relatively well covered and confluent
endothelial layers (Figure 20).

Table 4: Summary of number of adhered and non-adhered cells following 60 minute static
BVM incubation

Initial Cell
Count
Total Cells
Counted on
Scaffold
Average
Counted NonAdhered Cells
Total Cells in
BMV System

Scaffold A

% Initial
Cell
Count

6.00E+06

100%

6.79E+05

Scaffold B

% Initial
Cell
Count

Average

6.00E+06

100%

/

10.03%

10.68%

8.50%

6.82%

18.53%

17.50%

6.01E+05
11.33%

3.07E+05

5.10E+05
5.13%

9.86E+05

16.46%

1.11E+06

Figure 20: Representative BBI image of PLGA scaffold with HUVECs after 60 minutes of
static incubation
4.2.3 Discussion
The results of this experiment indicated that the majority of the cells that were harvested
from the cell culture flasks were not in the BVM system. As stated in the methods, once the
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HUVECs are harvested from the cell culture flasks they come in contact with a 50mL centrifuge
tube, a trough and a syringe. Therefore, it was hypothesized that cells may be remaining in these
locations and are not added to the BVM, contributing to the low percentages that are observed.
Another hypothesis to explain the lack of cells counted during analysis was that the pressure
sodding process was pushing cells far in to the pores of the scaffold and hence, were not visible
during en face imaging and image analysis.

4.3 Investigation of BVM Cell Harvest and Cell Sodding Efficiency
In attempt to explain the low number of cells accounted for after BBI image analysis and
Nexcelom Cellometer non-adhered cell counts, an experiment was designed to investigate the
possible locations where the cells could be lost. These locations included the centrifuge tube used
to pellet the cells, the trough used to hold the cell solution before sodding, the syringe used to add
the cells to the BVM and lastly, the pores of the scaffold. A study was designed to include one
BVM setup in which all possible locations were analyzed to determine if all the cells could be
accounted for. The full protocol for this setup can be found in Appendix B.2.
4.3.1 Methods
4.3.1.1 Cell Selection and Cell Culture
The methods described in the 6-well plate experiments in Chapter 2 were utilized to
select, and thaw one vial of P4 HUVECs (Section 2.2.1.2). The HUVECs were expanded to P6
and were used once the flask was 80% confluent.
4.3.1.2 Preparation of PLGA Scaffolds
One 15 wt% PLGA scaffold was electrospun by another student using previously
developed methods. One 4cm section was cut from the scaffold and sutured to luer lock fittings
on each side with a silk suture. The scaffold was sterilized in 70% EtOH, rinsed and primed as
described previously (Section 4.2.1.2).
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4.3.1.3 Preparation of Bioreactors and Dynamic Conditioning
The bioreactor was prepared and the scaffolds were conditioned and coated using the
same methods as the previous section (Section 4.2.1.3-4.2.1.4).
4.3.1.4 Pressure Sodding of HUVECs and Quantifying Lost Cells
At the end of the dynamic conditioning process, the bioreactor was removed from the
incubator and placed back in the hood for cell sodding. HUVECs were harvested from VWR
225mL cell culture flasks with 1X trypsin. The cells were centrifuged for 4 minutes and resuspended in 6mL of HUVEC media. After the cell solution was transferred to a trough, 1mL of
trypsin was added to the 50mL centrifuge tube to detach any remaining cells. The trypsin was
deactivated with 2mL of HUVEC media and samples from this solution were submitted to the
Nexcelom Cellometer for cell counts. After the cell solution was syringed in to the BVM via
pressure sodding, 1 mL of trypsin was added to the trough and syringe. After deactivation with
HUVEC media, samples from these solutions were also submitted to the Nexcelom Cellometer
for cell counts. Once the cells were sodded on the scaffold, the bioreactor was placed back in to
the large incubator and hooked up to the peristaltic pump. The pressure sodding was continued in
the incubator for one hour at 10rpm transmural flow. The bioreactor was then incubated statically
for one hour to allow for proper cell adhesion. The incubator was maintained at 37℃ and 5%
CO2.
4.3.1.5 Harvesting of Scaffolds and Non-Adhered Cells from Bioreactors
The scaffold was harvested and fixed in histochoice using the previously described
methods. The non-adhered cells were also obtained and counted as previously described (Section
4.2.1.6).
4.3.1.6 Fluorescent Microscopy
As before, to quantify the number of cells adhered to the luminal surface of the scaffold,
a BBI stain was used (Section 4.2.1.7). One cross section was cut from the scaffold to determine
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if cells were being forced in to the pores. The remaining scaffold was cut longitudinally to image
the lumen and obtain adhered cell counts.
4.3.1.6 Image Analysis
The same image analysis procedure described previously was used to quantify the
number of cells adhered to the lumen of the scaffold (Section 4.2.1.8).
4.3.2 Results
As seen in Table 4, the percentage of the initial cell count that was accounted for after
non-adhered cell counts and image analysis was 21.54%. This percentage was similar to the
percentage found in Section 4.2, suggesting that the lack of cells accounted for was not due to
experimenter error. However, the total percentage of cells found on surfaces throughout the BVM
setup was only 10.4%. This plus the number of cells quantified after image analysis and nonadhered cells counts (21.54%) resulted in a total of 32% of the cells being accounted for. The BBI
images of BVM cross-sections did not indicate that cells were being forced through the pores of
the scaffold (Figure 21). Finally, the en face BBI images of the scaffold indicated a well-covered
lumen similar to the scaffolds imaged in Section 4.3 (Figure 22).

Table 5: Summary of results obtained from Nexcelom Cellometer non-adhered cells counts
and ImageJ adhered cell counts
Initial Cell Count

6.46E+06

Adhered Cells on Scaffold

8.13E+05

12.60%

Non-Adhered Counted Cells

5.77E+05

8.94%

1.39E06

21.54%

Total Cells in BVM

Table 6: Summary of the number of cells found on surfaces throughout the BVM setup
Location
Trough
Syringe
50 mL Conical
Total

Number of Cells
4.26E+05
1.03E+05
1.46E+05
6.75E+05 (10.4%)
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Figure 21: Representative BBI image of PLGA scaffold cross-section. Image was taken at
4x.

Figure 22: Representative en face BBI image of BVM. Image was taken at 4x.
4.3.3 Discussion
The goal of this study was to determine if the number of unaccounted cells observed in
Section 4.2 could be found in the 50mL centrifuge tube used to pellet the cells, the trough used to
hold the cells during sodding, the syringe used to transfer the cells in to the BVM, or in the pores
50

of the scaffold. As seen in Tables 4 and 5, only one third of the initial cell count was accounted
for after including these locations in the analysis. While the locations analyzed in this study did
not contain all the unaccounted cells, the information obtained was still valuable. As seen in
Table 5, there were a substantial number of cells found in each location, indicating a potential
area of inefficiency in the BVM protocol. Therefore, it is important to keep these results in mind
during a BVM setup to reduce the number of cells lost during these stages of the protocol and
maximize the number of cells sodded on to the scaffold.
After further imaging and analysis, it was determined that the curved shape of the
scaffolds resulted in an incomplete field of focus. Therefore, because not all of the cells are in
focus in the images, they cannot be counted during image analysis. This conclusion helps to
reconcile the differences observed between the confluent en face BBI images and the low number
of cells accounted for. It was then hypothesized that the methods used to quantify the number of
adhered cells (BBI staining and image analysis) would be sufficient to detect a difference in the
number of cells adhered to scaffolds coated with different pre-coatings, even if all of the cells
were not accounted for. Although the unaccounted for cells could provide an area of investigation
for a separate project, it was determined to be outside the scope of this project. Because the aim
of this thesis is to compare the coatings, only the relative number of cells adhered was important
for analysis. To determine if this method was sufficient, a proof-of-concept study was developed
in which this method of analysis was used to compare the number of cells adhered to a coated
versus non-coated BVM.

4.4 Proof of Concept Study: Protocol Verification for BVM Coating
Comparison Studies
In the previous study it was concluded that the analysis of en face BBI images was sufficient
to determine which coating was more effective in increasing endothelial cell adhesion in a BVM.
One of the aims of this thesis was the determine which coating was most effective in increasing
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cell adhesion, therefore, accounting for all the cells added to the BVM system was not as
important as determining the relative number of cells adhered to coated scaffolds. To confirm that
only using cell counts of the BBI images in ImageJ was adequate to determine a difference in the
number of cells adhered to a scaffold, a small proof-of-concept study was designed. The goal of
this study was to compare the number of endothelial cells adhered to a BVM pre-coated with
Conditioning Media to a non-coated BVM using cell counts of BBI images in ImageJ. Because
the goal of this study was to determine if this analysis technique for BVM coating comparison
studies was appropriate, ProNectin-F was not used as a coating due to its high cost. The full
protocol for this setup can be found in Appendix B.3.
4.4.1 Methods
4.4.1.1 Cell Selection and Cell Culture
The same methods described in the 6-well plate experiments in Chapter 2 were utilized to
select, and thaw P4 HUVECs (Section 2.2.1.2). The HUVECs were expanded to P7 and were
used once the flasks were 80% confluent.
4.4.1.2 Preparation of PLGA Scaffolds
Three 15 wt% PLGA scaffolds were electrospun by another student using previously
developed methods. Six 4cm sections were cut from the scaffolds and sutured to luer lock fittings
on each side with a silk suture. The scaffolds were the sterilized in 70% EtOH for 30 minutes.
After sterilization, each scaffold was syringe-rinsed with PBS. The three scaffolds to be precoated with Conditioning Media were syringe-primed (Section 4.2.1.2) with Conditioning Media.
The three scaffolds that were non-coated were flushed with only DCF-PBS.
4.4.1.3 Preparation of Bioreactors
Bioreactor media and Conditioning Media were warmed to 37℃ in a water bath. Using
aseptic technique, bioreactor media was added to each bioreactor that housed a coated scaffold.
DCF-PBS was added to the bioreactors that housed non-coated scaffolds. The media reservoirs
for the coated scaffolds were filled with Conditioning Media, while the reservoirs for non-coated
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scaffolds were filled with DCF-PBS. The rinsed and primed scaffolds were then inserted in to the
bioreactors. The bioreactors with the scaffolds and media reservoirs were then placed in a large
incubator and hooked up to a peristaltic pump
4.4.1.4 Dynamic Conditioning
Each bioreactor was primed using the peristaltic pump to remove all air from the systems.
After priming, transluminal flow was restricted, forcing Conditioning Media or DCF-PBS
through the pores of the scaffolds at 150rpm. The dynamic conditioning of the scaffolds was
continued for 20 minutes.
4.4.1.5 Pressure Sodding of HUVECs
The same methods described in Section 4.2.1.5 were utilized to sod the HUVECs to each
scaffold.
4.4.1.6 Harvesting of Scaffolds
After 60 minutes of static incubation, the same methods described in section 4.2.1.6 were
utilized to harvest the coated and non-coated scaffolds from the bioreactors. No non-adhered cell
counts were obtained during this study.
4.4.1.7 Fluorescent Microscopy
The same methods described in Section 4.2.1.7 were utilized to stain and image the
scaffolds.
4.4.1.8 Image Analysis
The same methods described in Section 4.2.1.8 were utilized to analyze each en face BBI
image of the six scaffolds.
4.4.1.9 Statistical Analysis
To determine if there was a significant difference in the number of cells adhered to a noncoated or coated scaffold, a student’s t-test was used where α was equal to 0.05.
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4.4.2 Results
After cell counts were performed in ImageJ for all six scaffolds, it was determined that there
was significantly more cells adhered to the scaffolds coated with Conditioning Media compared
to a non-coated scaffold after 60 minutes of static incubation (Figure 23). The BBI images also
illustrated a more confluent layer of cells throughout the coated scaffolds compared to non-coated
scaffolds (Figure 24).

Total Adhered Cells After 60 Minute Static
BVM
6.00E+05
Number of Adhered Cells

*
5.00E+05
4.00E+05

3.00E+05
2.00E+05
1.00E+05
0.00E+00
Coated Scaffold

Non-Coated Scffold

Figure 23: Number of counted cells adhered to coated and non-coated scaffolds from BBI
images. n=3. *p<0.05
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Figure 24: Representative images of Conditioning Media coated and non-coated scaffolds at
10x. The scaffolds coated with Conditioning Media had better cell coverage that scaffolds
that were not pre-coated
4.4.3 Discussion
In order to successfully determine which pre-coating is the most effective in increasing
endothelial cell adhesion in a BVM, a protocol had to be established to compare the coatings to
one another. The results from this proof-of-concept study indicate that performing cell counts on
BBI images in ImageJ was sufficient to detect a significant difference in the number of cells
adhered between the coated and non-coated scaffolds. This method also allows for a qualitative
form of analysis in which coating effectiveness can also be evaluated by the relative cell
coverage, in addition to the cell counts. The results of this study indicate that the use of
Conditioning Media, the pre-coating currently implemented in to the BVM, significantly
increased the number of cells adhered to the scaffold. This result verifies the need for a precoating and the dynamic conditioning stages. However, as previously stated, one of the
limitations of the current BVM system is the lack of cell attachment after flow exposure. This
raises a few questions: Is the increase in cell adhesion due to the pre-coatings increasing the
number of cells that adhere initially? Do the pre-coatings reduce the number of cells that are lost
after the scaffolds are exposed to physiologic shear forces, or is it a combination of the two? With
these questions in mind, two comparison studies were designed to determine the mechanism of

55

action of the pre-coatings as well as to determine if Conditioning Media or ProNectin-F was the
most effective coating in increasing cell adhesion when implemented in to the BVM system.
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CHAPTER 5: BVM PRE-COATING COMPARISON STUDIES
As previously stated, ProNectin-F was consistently found to be successful clinically in
increasing endothelial cell adhesion in a TEVG [52, 54, 59]. In some of these studies, it was
concluded that the cells were able to create a stronger attachment to the materials that were coated
with ProNectin-F when compared to other materials because significantly less cells “washed off”
the material once it was exposed to flow [50, 77]. It was hypothesized that less cells detached
following flow exposure because the cells had undergone receptor mediated cell adhesion and
cytoskeletal remodeling [48, 77-79]. When the ECM peptides in ProNectin-F or Conditioning
Media are adsorbed to the polymer surface, the cells bind specific amino acid sequences of these
molecules via integrin receptors, initiating signaling cascades such as cells spreading,
proliferation and differentiation [79] . As described in Chapter 1, when the interactions between
the membrane integrins and ECM proteins do not occur, endothelial cells will undergo apoptosis
[58]. Therefore, when adding endothelial cells to the scaffold of a BVM, it is important to ensure
that receptor mediated adhesion occurs to both increase the number of cells adhered as well as
activate the crucial pathways that are necessary for cell viability. When utilizing pre-coatings in a
BVM, there are two potential stages in which they can play a role in increasing endothelial cell
adhesion: increasing the number of cells that adhere initially, prior to flow exposure; or reducing
the number of cells that are lost after the BVM is exposed to physiologic shear forces. Hence, two
comparison studies were designed to determine which stage Conditioning Media and ProNectin-F
act to increase cell adhesion, as well as to determine which coating was more effective in
increasing overall cell adhesion in a BVM.

5.1 Static BVM Coating Comparison Study
As previously stated, there are two stages in the BVM setup in which Conditioning Media
and ProNectin-F can act to increase endothelial cell adhesion. The first was increasing the
number of cells that adhere to scaffold initially after pressure sodding and before fluid flow
exposure. To determine if pre-coatings increased the number of cells adhered after pressure
57

sodding, a comparison study was designed to quantify the number of endothelial cells adhered to
a non-coated, Conditioning Media coated and ProNectin-F coated PLGA scaffolds after 60
minutes of static incubation. This study also served to determine what type of cell adhesion was
occurring (receptor mediated/non-receptor mediated) and determine if the extent of cell spreading
could be quantified. The full protocol for this setup can be found in Appendix B.4.
5.1.1 Methods
5.1.1.1 Cell Selection and Cell Culture
The same methods described in the 6-well plate experiments in Chapter 2 were utilized to
select, and thaw P4 HUVECs (Section 2.2.1.2). The HUVECs were expanded to P8 and were
used once the flasks were 80% confluent.
5.1.1.2 Preparation of PLGA Scaffolds
Three 15 wt% PLGA scaffolds were electrospun by another student using previously
developed methods. Nine 4cm sections were cut from the scaffolds and sutured to luer lock
fittings on each side with a silk suture. The scaffolds were then sterilized in 70% EtOH for 30
minutes. After sterilization, each scaffold was syringe-rinsed with PBS. The three scaffolds to be
pre-coated with Conditioning Media were syringe-primed (Section 4.2.1.2) with Conditioning
Media. The three scaffolds that were non-coated were flushed with only PBS. The three scaffolds
to be pre-coated with ProNectin-F were syringe primed with ProNectin-F diluted in HUVEC
media.
5.1.1.3 Preparation of Bioreactors
Bioreactor media and Conditioning Media were warmed to 37℃ in a water bath. Using
aseptic technique, bioreactor media was added to each bioreactor that housed a coated scaffold.
DCF-PBS was added to the bioreactors that housed non-coated scaffolds. The media reservoirs
for the coated scaffolds were filled with Conditioning Media or ProNectin-F diluted in HUVEC
media, while the reservoirs for non-coated scaffolds were filled with DCF-PBS. The rinsed and
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primed scaffolds were then inserted in to the bioreactors. The bioreactors with the scaffolds and
media reservoirs were then placed in a large incubator and hooked up to a peristaltic pump.
5.1.1.4 Dynamic Conditioning
Each bioreactor was primed using the peristaltic pump to remove all air from the systems.
After priming, transluminal flow was restricted, forcing Conditioning Media, ProNectin-F or
DCF-PBS through the pores of the scaffolds at 150rpm. The dynamic conditioning of the
scaffolds was continued for 20 minutes.
5.1.1.5 Pressure Sodding of HUVECs
The same methods described in Section 4.2.1.5 were utilized to sod the HUVECs to each
scaffold.
5.1.1.6 Static Incubation and Harvesting of Scaffolds
After 60 minutes of static incubation, the same methods described in section 4.2.1.6 were
utilized to harvest the coated and non-coated scaffolds from the bioreactors.
5.1.1.7 Fluorescent Microscopy
The same methods for a BBI stain described in Section 4.2.1.7 were utilized to quantify
the number of endothelial cells adhered to each scaffold after 60 minutes of static incubation. To
indirectly assess the type and strength of the cell adhesion, a rhodamine phalloidin (Em λ 570
nm) stain was used. The protocol for the rhodamine phalloidin stain can be found in Appendix
C.2. Images of each scaffold were obtained using an Olympus fluorescent microscope.
5.1.1.8 Image Analysis
The same methods described in Section 4.2.1.8 were utilized to analyze each en face BBI
image. ImageJ was also used to analyze the rhodamine phalloidin images to quantify cell
spreading. The freehand selection tool was utilized to trace all cells in focus with clearly
distinguishable borders (Figure 25). The measure function within ImageJ Analysis was then used
to quantify the traced perimeter of the cell. The measured perimeters were then averaged to obtain
an average cell perimeter for that image. This was repeated for the eight images representing each
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scaffold. These eight values were then averaged to obtain an average cell perimeter for each
scaffold. Like the BBI image analysis, a Ranchi Ruling was used to convert the value from pixels
to μm.

Figure 25: Illustration of rhodamine phalloidin image analysis using freehand tracing in
ImageJ.
5.1.1.9 Statistical Analysis
To determine if there was a significant difference in the number of cells adhered to a noncoated or coated scaffold, ANOVA and students t-test was used where α was equal to 0.05.
5.1.2 Results
As seen in Figure 26, after 60 minutes of static incubation, there were significantly more
endothelial cells adhered to PLGA scaffolds coated with Conditioning Media and ProNectin-F
compared to the non-coated control. However, there was not a significant difference in the
number of endothelial cells adhere to PLGA scaffolds coated with Conditioning Media or
ProNectin-F after 60 minutes of static incubation. As illustrated in Figure 27, the scaffolds that
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were pre-coated with Conditioning Media or ProNectin-F had a more confluent endothelial cell
layer compared to the non-coated control.

Figure 26: Number of endothelial cells adhered to scaffolds that were non-coated, coated
with Conditioning Media or coated with ProNectin-F after 60 minutes of static incubation
in a BVM. n=3. *p<0.05 compared to non-coated

Figure 27: Representative BBI images of non-coated, Conditioning Media coated and
ProNectin-F coated scaffolds after 60 minutes static incubation in a BVM.

As seen in Figure 28, the cells adhered to scaffolds coated with Conditioning Media or
ProNectin-F had significantly larger cell perimeters compared to non-coated scaffold. In addition,
it was found that cells adhered to scaffolds coated with ProNectin-F had significantly larger cell
perimeters than cells adhered to scaffolds coated with Conditioning Media. These results were
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confirmed qualitatively. As seen in Figure 29, the cells adhered to coated scaffolds had undergone
cell spreading and changed shape whereas the cells adhered to non-coated scaffolds did not.

**

Figure 28: Endothelial cell perimeters of cells adhered to non-coated, Conditioning Media
coated and ProNectin-F coated scaffolds after 60 minutes of static incubation in a BVM.
n=3. *p<0.05 compared to non-coated scaffolds. **p<0.05 compared to Condition

Figure 29: Representative rhodamine phalloidin images of non-coated, Conditioning Media
coated and ProNectin-F coated scaffolds after 60 minutes of static incubation in a BVM
5.1.3 Discussion
As seen in the BBI images (Figure 27) and quantitative image analysis (Figure 26), precoating PLGA scaffolds with Conditioning Media and ProNectin-F resulted in significantly more
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cells adhered after 60 minutes of static incubation in a BVM. This indicates that the pre-coatings
do play a role in increasing the initial number of cells that adhere to a PLGA scaffold after
pressure sodding, which is consistent with the results from the proof of concept study. But as
previously stated, there was not a significant difference in the number of cells adhered to
scaffolds coated with Conditioning Media or ProNectin-F, indicating that Conditioning Media
was just as effective as ProNectin-F in increasing the number of endothelial cells adhered after 60
minutes of static incubation. However, as seen in the rhodamine phalloidin images (Figure 29)
and quantitative image analysis (Figure 28), the cells that adhered to scaffolds coated with
ProNectin-F underwent more cell spreading, indicating a stronger attachment to the scaffold [58].
This was thought to have occurred in response to the multitude of proteins in Conditioning Media
that are adsorbed to the scaffold surface. As previously stated, proteins that play a role in cell
adhesion, such as fibronectin and laminin, make up a small percentage of serum [58, 64]. Hence,
there are fewer proteins for the integrins on the cell membranes to bind to and initiate cell
spreading signaling cascades when Conditioning Media is used as a pre-coating. In comparison,
ProNectin-F is made up of the RGD cell attachment epitope from fibronectin interspersed
between structural peptides, resulting in more interactions between the cell membrane integrins
and the adhesion peptides, initiating more cell spreading signaling cascades and creating a
stronger cell attachment [80]. As previously stated, one of the current limitations of the BVM is
the lack of cell adhesion after exposure to physiologic fluid flow. Therefore, the extensive cell
spreading observed in ProNectin-F coated scaffolds may decrease the number of cells lost after
fluid flow exposure.

5.2 Dynamic BVM Comparison Study
The second stage that pre-coatings can act to increase cell adhesion in a BVM is
reducing the number of cells lost after flow exposure. To determine if Conditioning Media and
ProNectin-F prevented cell loss after flow exposure, and if one coating was more efficient than
the other in doing so, a second comparison study was designed. This comparison study sought to
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quantify and compare cell spreading and number of cells adhered to scaffolds that were coated
with Conditioning Media, ProNectin-F and PBS (non-coated). The full protocol used for this
setup can be found in Appendix B.5.

5.2.1 Methods
5.2.1.1 Cell Selection and Cell Culture
The same methods described in the 6-well plate experiments in Chapter 2 were utilized to
select, and thaw P4 HUVECs (Section 2.2.1.2). The HUVECs were expanded to P8 and were
used once the flasks were 80% confluent.
5.2.1.2 Preparation of PLGA Scaffolds
The same methods described in Section 5.1.1.2 were utilized to prepare the PLGA
scaffolds for the dynamic comparison study.
5.2.1.3 Preparation of Bioreactors
The same methods described in Section 5.1.1.3 were utilized to prepare the PLGA
scaffolds for the dynamic comparison study.
5.2.1.4 Dynamic Conditioning
The same methods described in Section 5.1.1.4 were utilized to condition and pre-coat
the scaffolds in the dynamic comparison study.
5.2.1.5 Pressure Sodding of HUVECs
The same methods described in Section 4.2.5 were utilized to sod the HUVECs to each
scaffold.
5.2.1.6 Incubation, Flow Exposure and Harvesting of Scaffolds
After 60 minutes of static incubation, the scaffolds were exposed to 10rpm of
transluminal flow. After this, the transluminal flow was increased by 15 rpm every hour until
90rpm was reached (took about 6 hours). After 60 minutes at 90rpm, the scaffolds were harvested
from the bioreactors using the methods described in Section 4.1.6.
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5.2.1.7 Fluorescent Microscopy
The same methods described in Section 5.1.1.7 were utilized to stain and image the
scaffolds for the dynamic comparison study.
5.2.1.8 Image Analysis
Quantitative
The same methods described in Section 5.2.1.8 were utilized to quantify cell spreading
and the number of cells adhered to the scaffolds used in the dynamic comparison study.
Qualitative
After being exposed to fluid flow, the cells in the rhodamine phalloidin images had less
distinct borders, making it more difficult to quantify cell spreading. Hence, to supplement the
quantitative image analysis, two qualitative forms of analysis were utilized. The first of which
was to count the number of traceable cells in each image. As previously stated, the cells traced in
the rhodamine phalloidin images for quantitative images had to be in focus and have a defined
border. Assuming that there was a positive correlation between cell coverage and number of
traceable cells, this measure could supplement both the cell counts from the BBI images and the
traces from the rhodamine phalloidin images. The second qualitative measure used was a scale of
cell coverage. A 10 point scale was used for each image where a 10 was 100% of the image was
covered cells and a 1 was 0-1% of the image was covered by cells (Figure 30).

Figure 30: Rhodamine phalloidin images representing a 1, 5 and 10 on the qualitative cell
coverage scale
5.2.1.9 Statistical Analysis
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To determine if there was a significant difference in the number of cells adhered to a noncoated or coated scaffold, ANOVA and students t-test was used where α was equal to 0.05.

5.2.2 Results
As seen in Figures 31 and 32, there were significantly more cells adhered to scaffolds
coated with Conditioning Media o ProNectin-F than non-coated scaffolds after 60 minutes of
transluminal flow at 90 rpm. There was not a significant difference in the number of cells adhered
to Conditioning Media versus ProNectin-F coated scaffolds. After quantitative analysis of the
rhodamine phalloidin images, it was found that the cells adhered to Conditioning Media and
ProNectin-F coated scaffolds had significantly larger traced perimeters when compared to the
non-coated control scaffolds (Figures 33,34). The supplemental qualitative rhodamine phalloidin
image analysis resulted in more cells traced and higher coverage scores for Conditioning Media
and ProNectin-F images compared to non-coated images, while the number of cells traced and
coverage scores for Conditioning Media and ProNectin-F images were very similar (Tables 6,7).

Number of Cells Adhered After 60 Minutes
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Figure 31: Results of BBI image analysis for cells adhered to non-coated, Conditioning
Media coated and ProNectin-F coated scaffolds after 60 minutes of transluminal flow at
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90rpm. n=3. *p<0.05 compared to non-coated control

Figure 32: Representative BBI images of non-coated, Conditioning Media coated and
ProNectin-F coated scaffolds after 60 minutes of transluminal flow at 90 rpm

Cell Perimeter

Traced Cell Perimeter After 60 Minutes of
90rpm Transluminal Flow
180
160
140
120
100
80
60
40
20
0
Non-Coated

*

*

Conditioning Media

ProNectin-F

Figure 33: Results of traced cell perimeters from rhodamine phalloidin image analysis for
non-coated, Conditioning Media coated and ProNectin-F coated scaffolds after 60 minutes
of transluminal flow at 90rpm. n=3. *p<0.05 compared to non-coated control
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Figure 34: Representative rhodamine phalloidin images of non-coated Conditioning Media
coated and ProNectin-F coated scaffolds after 60 minutes of trasnluminal flow at 90rpm
Table 7: Summary of the number of cells traced in rhodamine phalloidin images for noncoated, Conditioning Media and ProNectin-F rhodamine phalloidin images

Non-Coated
20.3

Number of Traces
Conditioning Media
35.6

ProNectin-F
37.0

Table 8: Summary of cell coverage scores of non-coated, Conditioning Media and
ProNectin-F rhodamine phalloidin images
Qualitative Coverage Score (1-10)
Non-Coated

Conditioning Media

ProNectin-F

2.7

7.3

7.6

5.2.3 Discussion
The limitation of the BVM system that was studied for this thesis was the lack of cells
adhered to PLGA scaffolds after exposure to fluid flow. This thesis sought to determine if
utilizing a different pre-coating could overcome this limitation and increase the number of cells
adhered as well as determine which coating was the most efficient in doing so. The results of the
dynamic comparison study indicate Conditioning Media is as effective as ProNectin-F in
retaining cell attachment after fluid flow exposure. It was concluded that the coatings encouraged
receptor mediated cell adhesion because cell spreading and changes in cell shape were not
observed on non-coated scaffolds. The cells adhered to non-coated scaffolds remained “balled
68

up” indicating non-receptor mediated cell adhesion. The Conditioning Media and ProNectin-F
rhodamine phalloidin images and qualitative image analysis also illustrate that the scaffolds were
well covered after 60 minutes of transluminal flow exposure at 90rpm.These images also suggest
a slight change in cell morphology in the direction of flow, while it was not extensively studied or
quantified for this thesis.
In the static comparison study it was found that the cells adhered to ProNectin-F coated
scaffolds were significantly more spread out than cells adhered to Conditioning Media coated
scaffolds. Therefore, these results indicate that given more time (7 additional hours) and flow
exposure, the cells adhered to Conditioning Media coated scaffolds were as spread out as cells
adhered to ProNectin-F coated scaffolds. Hence, although the cell adhered to ProNectin-F coated
scaffolds had larger perimeters after flow exposure, indicating a stronger attachment, the cells
adhered to Conditioning Media coated scaffolds were able to undergo more cell spreading and
remain attached after flow exposure.

5.3 Discussion of BVM Pre-coating Experiments
An interesting result of the comparison studies was the enhancement of cell spreading of
the cells adhered to Conditioning Media coated scaffolds after exposure to flow conditions. It is
possible that due to competitive protein adsorption and less interactions between cell membrane
integrins and the ECM proteins on Conditioning Media coated scaffolds, that it takes more time
for the change in cell shape and cell spreading to occur. Studies examining the dynamics and
mechanics of endothelial cell spreading found that the rate and the extent of cell spreading
increases with the density of the ligand substrate[81]. The exposure to shear stress may also play
a role in the observed increase in cell spreading for Conditioning Media coated scaffolds. Studies
that have compared the transcriptional profiles in endothelial cells exposed to prolonged laminar
shear stress or turbulent flow compared to static controls found an upregulation in gene products
involved in cytoskeletal remodeling, survival, and antioxidation [82]. These studies also found
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that in addition to the upregulation of various transcription factors, shear stress also activates
integrins and increases their affinity for ECM proteins [82]. Compared to static controls,
endothelial cells exposed to physiologic shear stresses had a significant increase in the number of
integrin receptors and their reattachment to the ECM. Therefore, it is possible that although the
cells adhered to Conditioning Media coated scaffolds are less spread out in static conditions, once
they are exposed to transluminal flow these mechanisms are activated and the cells undergo more
extensive cytoskeletal remodeling and form stronger attachments.
As previously stated, Conditioning Media is the pre-coating that is currently implemented
in the BVM system for which low numbers of attached cells have been observed [5, 73, 75].
However, the results of this dynamic comparison study indicate a relatively well covered scaffold
when Conditioning Media was used as a pre-coating. This difference can be attributed to a
multitude of factors. In this dynamic comparison study, the dynamic conditioning stage was
reduced from overnight to twenty minutes due to values repeatedly cited in literature [50, 52, 54,
59] . In these studies, optimum cell adhesion was found after 10-45 minutes of coating incubation
[50, 52, 54, 59]. Therefore, by utilizing a more optimal coating incubation period, the coatings
may have been more effective than when they are allowed to incubate overnight. Also, the length
of transluminal flow exposure was reduced from 3-7 days to 7 hours. While it is possible that a
longer time point for flow exposure would result in a higher number of cells lost, many studies
examining the effects of flow on endothelial cell retention to a TEVG found that the majority of
cell loss usually occurred within the first 45 minutes to two hours once physiologic flow was
reached and was insignificant after 24 hours [83, 84].
Finally, another factor that may contribute to the increased cell retention when
Conditioning Media was used as a pre-coating is variation between researchers. The cell retention
in a BVM may be influenced by the experience of the researcher (how many times they have set
up a BVM), efficiency of the cell harvesting and sodding stages, and proper priming and
70

conditioning. Because this thesis required a large number of BVM setups and specifically
investigated the need to consider harvesting and sodding process efficiency, more successful
setups may have been a result of these experiences.
In conclusion, the studies in this Chapter indicate that Conditioning Media is as efficient
as ProNectin-F in increasing endothelial cell retention as well as encouraging receptor mediated
cell adhesion and cell spreading after exposure to transluminal flow. As discussed in Section 4.1,
the cost to use ProNectin-F as a pre-coating in the BVM system is 30 times the cost of
implementing Conditioning Media. Therefore, because Conditioning Media is extremely cost
efficient, as well as effective, it appears to be the most appropriate pre-coating to be implemented
in to the BVM system.
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CHAPTER 6: DISCUSSION AND CONCLUSIONS
6.1 Overview and Summary
One in three adults is diagnosed with cardiovascular disease in the United States and it is
currently the leading cause of death in developing countries [6]. These astounding statistics
solidify the need for the development and use of effective therapies to treat cardiovascular disease
and its symptoms. One of the most effective and widely used therapies to date is intravascular
stents [1]. However, as previously stated, stent designs are constantly being modified to increase
their effectiveness and prevent thrombotic events [2]. The evaluation of new stent designs and
their functionality require bench, in vitro and in vivo testing [85]. Currently, bench testing
provides a controlled environment to evaluate specific properties such as mechanical durability,
fatigue and expansion [85]. In vitro testing consists of the initial evaluation of biocompatibility
via methods such as cytotoxicity testing [85]. In vivo testing investigates the sensitivity,
inflammatory response, and systemic effects of the device in a living organism [85]. All three
phases of testing are required to complete an analysis of the safety and effectiveness of the device
before it can be studied and implanted in humans. However, there is currently a large gap
between in vitro and in vivo testing that if bridged, could create a more efficient testing process
for medical devices. The BVM seeks to bridge this gap for intravascular devices by providing an
in vitro model that represents a physiologic system that is both cost and time efficient. The
development of the BVM will allow for a more thorough initial analysis of stents due to its ability
to mimic key aspects of a native vessel in vitro.
Currently the BVM utilizes a PLGA scaffold, which has been shown to be biocompatible
and support the attachment and proliferation of endothelial cells, essentially mimicking the intima
of the native artery [86]. While PLGA is a proven scaffold material for tissue engineering, it has
limitations that need to be overcome for it to be successful in the BVM system [17, 39, 41, 86].
One of these limitations is that because it is a synthetic polymer scaffold, it is devoid of any
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biological components, which limits cell adhesion. Without a confluent endothelial cell layer
throughout the lumen of the scaffold, the interactions observed between the device and the BVM
will be difficult to assess. To address the limitation of the lack of endothelial cell adhesion to
PLGA scaffolds in a BVM, Conditioning Media (serum enhanced media) has been utilized to precoat the scaffolds prior to adding cells. However, after exposure to flow conditions, the cells were
not retained and a confluent endothelial layer was not achieved. To address the lack of cell
adhesion in the current BVM system, different pre-coatings were evaluated and compared to one
another to determine which was most efficient in increasing endothelial cell adhesion in a BVM.
The lack of cell adhesion after flow exposure is a limitation that is shared by Tissue
Engineered Vascular Grafts [3, 37, 44, 55]. To overcome this limitation, the lumen of grafts has
been pre-coated with various ECM proteins, improving endothelial cell adhesion and retention
after flow exposure [50, 52-54]. Pre-coatings that have been utilized in previous studies include
collagen, laminin, fibronectin, serum and the ECM in its entirety. Clinically, fibronectin is the
peptide sequence that has been most successfully used for improving cellular attachment and
retention [52-55, 77]. Giudiceandre et al. found that fibronectin significantly improved cellular
attachment and retention as compared with uncoated grafts of ePTFE, Dacron and MyoLink [48].
Thompson et al. conducted a comparative study that found fibronectin significantly enhanced
cellular attachment compared to collagen, gelatin, laminin, and albumin [87]. However, Hess et
al. found that combinations of fibronectin and collagen, fibronectin and laminin, and fibronectin
and ECM were superior in enhancing endothelial cell adhesion compared to fibronectin, laminin,
and collagen alone [88]. Because fibronectin has been proven successful in increasing endothelial
cell attachment to TEVGs, it was chosen to be evaluated for implementation in the BVM system.
To improve the endothelial cell attachment and retention in the BVM, this thesis
characterized ProNectin-F (engineered fibronectin) and Conditioning Media (current BVM precoating) and compared their ability to increase endothelial cell attachment to 6-well plates and
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PLGA scaffolds in the BVM. The following discussion summarizes the work performed in this
thesis.
The first step of this thesis was to characterize the effects of ProNectin-F and
Conditioning Media in a more efficient and controlled setting using 6-well plates. To do this, a
protocol was developed to quantify the number of endothelial cells adhered to a pre-coated well
utilizing the Bioscience Nexcelom Cellometer. After four rounds of protocol development, the
final protocol included a centrifugation and re-suspension stage, decreasing the cell suspension
volume such that automated counts could be obtained for both adhered and non-adhered cells in
pre-coated 6-well plates. This protocol was then utilized in 6-well plate incubation time studies
and coating comparison studies.
Before evaluating the effectiveness of Conditioning Media and ProNectin-F in increasing
endothelial cell adhesion in 6-well plates, the coating and incubation times were analyzed to
determine their effects on cell adhesion. The results of these studies indicated that varying the
amount of time that the coated surfaces are incubated prior to adding cells does not affect the
number of cells that adhered to the coated surface. However, an increasing trend was observed for
the number of cells that adhered to the coated surface as the cell incubation time increased.
Hence, it was concluded that the time that the cells incubate on the coated surface played a more
dominant role in increasing cell adhesion in 6-well plate experiments. Therefore, in the 6-well
plate comparison studies a coating incubation time of twenty minutes was used while the cell
incubation time was varied in attempt to optimize cell adhesion.
To gain initial insight and data concerning the effectiveness of Conditioning Media and
ProNectin-F in increasing endothelial cell adhesion, a comparison study was designed to quantify
the number of cells adhered to coated and non-coated wells after 60 and 90 minutes of incubation.
After both 60 and 90 minutes of incubation, there were significantly more cells adhered to wells
coated with Conditioning Media or ProNectin-F compared to non-coated wells. However, no
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significant difference was found in the number of cells adhered to Conditioning Media coated
wells versus ProNectin-F coated wells at either time point. As previously stated, the 6-well plate
experiments served as a controlled environment to gain initial insight into the effects of the precoatings on cell adhesion. These conditions did not represent that of a dynamic vessel in which
factors such as vessel geometry and shear forces can effect cell attachment. Therefore, the precoatings were implemented in the BVM system to determine which was more effective in
increasing adhesion and retaining endothelial cells.
One of the projected benefits of a fully endothelialized BVM is that it will help to create
a more cost efficient approval testing process for intravascular devices. Therefore, if pre-coatings
are to be implemented in to the BVM it is important that they are also relatively cost efficient.
Hence, before implementing the ProNectin-F in to BVM setups, a cost analysis was performed to
compare it to the current pre-coating, Conditioning Media. It was determined that implementing
ProNectin-F in the BVM setup is 30 times more expensive than using Conditioning Media as a
pre-coating ($166.46 vs. $5.21). However, ProNectin-F was documented as a very successful precoating in increasing endothelial cell adhesion to polymer scaffolds of tissue engineered grafts
[53, 54, 77]. Hence, both coatings were utilized in BVM setups for comparison studies to
determine which coating was most effective in encouraging cell adhesion.
Utilizing a pre-coating in the BVM system potentially serves to both increase
initial endothelial cell attachment as well as prevent cell loss once the BVM is exposed to flow
conditions. Two comparison studies were designed to compare the effectiveness of ProNectin-F
and Conditioning Media in performing both of these functions. A static comparison study was
first conducted to determine which coating was more efficient in increasing the initial endothelial
cell attachment to a PLGA scaffold prior to flow exposure. In addition to quantifying the number
of cells adhered via BBI staining, the strength of the attachment was also quantified via
rhodamine phalloidin staining. It was found that significantly more cells adhered to scaffolds
coated with Conditioning Media or ProNectin-F, but there was not a significant difference in the
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number of cells adhered to Conditioning Media versus ProNectin-F coated scaffolds prior to flow
exposure. As expected, because the pre-coatings encourage receptor-mediated cell adhesion, the
cells adhered to coated scaffolds had significantly larger perimeters, indicating a stronger
attachment. Interestingly, the cells adhered to ProNectin-F coated scaffolds had significantly
larger perimeters than cells adhered to Conditioning Media coated scaffolds, suggesting a
stronger attachment.
To determine if the cells were in fact making stronger attachments to coated scaffolds, a
dynamic comparison study was conducted to determine which coating was more effective in
reducing the number of cells lost after exposure to transluminal flow. After 60 minutes of
transluminal flow at 90rpm, significantly more cells remained adhered to coated scaffolds when
compared to non-coated scaffolds. Again, after analyzing the BBI images, there was not a
significant difference in the number of cells that remained adhered to scaffolds pre-coated with
Conditioning Media or ProNectin-F. However, after analyzing the rhodamine phalloidin images it
was found that there was no longer a significant difference in the perimeter of cells adhered to
Conditioning Media or ProNectin-F coated scaffolds. Therefore, the comparison studies
combined indicated that Conditioning Media is as effective as ProNectin-F in increasing initial
cell attachment and retaining cell attachment after flow exposure in the BVM.

6.2 Challenges and Limitations
There were some key limitations in implementing and comparing the effectiveness of
pre-coatings in the BVM. One limitation was the inability to account for all of the cells added to
the system through image analysis and non-adhered cell counts. While it was not necessary for
the aims of this thesis, the inability to account for all the cells added made it difficult to compare
the calculated cell densities to values found in literature for pre-coated vascular grafts (usually
documented as % adhered). In addition to comparing cell densities to pre-coated TEVGs, it will
also be important to be able to compare the cell density of the BVM to cell densities of native
vessels. Being able to compare adhered cell densities is important because the ultimate goal of the
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BVM is to model a native endothelium in vitro. Therefore, in order to be considered an adequate
testing platform for intravascular devices, values such as cell density should be comparable to
documented in vivo values.
Another limitation of this study was the difficulty in clearly defining the cytoskeletons of
individual cells during the analysis of the rhodamine phalloidin images. While about 30 cells per
image had distinguishable borders, being able to trace all the cells in the rhodamine phalloidin
images would increase the accuracy of the cell spreading analysis. The rhodamine phalloidin
protocol had not been optimized for en face staining of PLGA scaffolds, which may have
contributed to the lack of definition of the stained cytoskeleton.

6.3 Future Work
6.3.1 Comparison Studies with Coating Combinations
It was stated in literature that fibronectin was more efficient in increasing cell adhesion
when combined with other ECM proteins such as collagen and laminin compared to fibronectin
alone [52-54]. While ProNectin-F and Conditioning Media effectively increased cell attachment
and retention to PLGA scaffolds when compared to non-coated scaffolds, a completely confluent
monolayer throughout the scaffold was not observed. Therefore, a combination coating could be
implemented to further improve cell attachment and retention in the BVM system. Another
combination that can be considered is ProNectin-F and Conditioning Media. In the experiments
for this thesis, ProNectin-F was diluted in HUVEC cell culture media. However, in future studies
ProNectin-F could be diluted in Conditioning Media, possibly combining their effects while
making ProNectin-F more cost-efficient.
6.3.2. Utilizing the ECM as a Pre-Coating
A multitude of proteins in the ECM play a role in cell adhesion [58]. Therefore, rather
than using a single adhesion protein or a combination of two, the ECM in its entirety could be
implemented in to the BVM system as a pre-coating to enhance cell attachment and retention.
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Aubrey Smith, a previous researcher in our lab, developed an ECM pre-coating of decellularized
porcine vessels that were homogenized and dissolved such that it could be applied to scaffolds
and other materials. In the future, this coating could be characterized and implemented in to the
BVM system as a pre-coating to determine its effectiveness in increasing endothelial cell
adhesion.
6.3.3 Rhodamine phalloidin Stain and Imaging Protocol for PLGA
The rhodamine phalloidin protocol provides a range of concentrations acceptable for
staining cell cytoplasm. An optimal concentration should be determined for en face staining of
PLGA scaffolds for a more consistent and defined stain. With the optimization of this protocol,
more cells can be accurately traced in each image, resulting in a more complete quantitative
analysis of cell spreading in the BVM. Also, imaging the scaffolds at a higher magnification
could result in more clearly defined cell borders, enhancing the cell tracing capabilities during
image analysis. Finally, there were challenges when a dual stain of rhodamine phalloidin and BBI
was conducted. Therefore, during rhodamine phalloidin staining optimization, the simultaneous
staining with BBI should also be included.
6.3.4 Effects of Pre-Coatings on Gene Expression
As discussed in previous sections, when endothelial cells are exposed to shear, integrin
binding and activation activates multiple signaling cascades including the upregulation of genes
required for cytoskeletal remodeling, and downregulating genes linked to proliferation and
apoptosis. Multiple researchers in our lab are currently working to determine endothelial gene
expression in the BVM. Therefore, these methods can be applied to determine how cell coatings
and receptor-mediated cell adhesion affect gene expression within the BVM and how these
expression profiles compare to the native vessel.
6.3.5 Evaluating Receptor Mediated Cell Adhesion
While the occurrence of cell spreading on coated scaffolds in the BVM indicated that
receptor mediated cell adhesion could be occurring, it is important to confirm this with further
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studies. To verify that the observed cell spreading is the result of integrin-ECM protein
interactions, a monoclonal antibody specific to ligand-occupied integrins could be used. Jalali et
al. conducted a study to evaluate the interactions between endothelial cell integrins and ECM
proteins during exposure to fluid flow [89]. A monoclonal antibody, HUST-21 was utilized to
bind specifically to ligand occupied integins followed by the addition of FITC-conjugated goat
anti-mouse IgG for fluorescent imaging [89]. This type of stain could be utilized in our BVM
system to confirm the interaction between integrins and ECM proteins and that receptor mediated
cell adhesion is occurring on coated scaffolds.
6.3.6 Effects of Pre-Coatings on Smooth Muscle Cells
To develop a physiologically relevant BVM, cellularizing the scaffold with two native
cell types would more closely mimic the native artery. Smooth muscle cells could be sodded to
the coated scaffold in combination with endothelial cells to create a more accurate in vitro testing
platform. It would therefore be beneficial to determine the effects that Conditioning Media and
ProNectin-F have on smooth muscle cell attachment in the BVM. This project is currently
underway in our laboratory.

6.4 Conclusions
The potential of the BVM to be used for the pre-clinical evaluations of intravascular
devices is great. However, before this model can be utilized for this purpose, further optimization
of the BVM must be completed. A confluent endothelial lining in the lumen of the BVM scaffold
is crucial for this model to be physiologically relevant. Pre-coatings have the ability to increase
endothelial cell adhesion to synthetic polymers, such as PLGA, and retain attachment after flow
exposure. This research provided extensive documentation of the comparison of Conditioning
Media and ProNectin-F as pre-coatings in 6-well plates and the BVM. The results of these studies
indicate that Conditioning Media is as effective as ProNectin-F in increasing endothelial cell
attachment and retaining attachment after flow exposure. Conditioning Media is also extremely
cost-efficient making it more appropriate for the BVM system. However, neither of these
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coatings achieved a 100% confluent layer, therefore additional coatings, combinations of
coatings, or the ECM should be evaluated to continue to optimize cell adhesion and retention in
the BVM.
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APPENDIX A: 6-WELL PLATE PROTOCOLS AND
EXPERIMENTAL DETAILS
A.1 6-Well Plate Protocol #1
Six-Well Plate Coating Protocol
Date:
Material:
Cell Type:

.
.
.

Prep Five Days Prior
1. Prep T-75 flask for thawed cells with 20 ml of HUVEC media, allow to incubate for at least 30 min
2. Thaw 1 vial of HUVECs for T-75 flask
3. Pass cells in to T-75 flask
4. Feed cells day after thawing
5. If T-75 is confluent, pass cells in to T-225
6. Make sure T-225 is 80% confluent prior to set up date
Set Up Day
8. Obtain 3 six-well plates
a. Label wells 1-18

11

2

3

7

8
5

9

13

5

5

14

15

5

5

2

4

5

6

10

11

12

16

17

18

5

5

5

2

1,7,3: No Coating
2,8,14: Conditioning Media
3,9,15: HUVEC Media
4, 10, 16: ProNectin-F+HUVEC Media
5, 11,17: ProNectin-F +PBS
6, 12,18: HUVEC Media w/5 Minute Cell Incubation

7. Preparation of Wells
a. Add 1.5ml of Conditioning Media in to wells 2, 8 and 14
b. Add 1.5ml of HUVEC Media in to wells 3, 9 and 15 and 6, 12, 18.
c. Add 1.5ml of ProNectin-F+HUVEC Media in to wells 4, 10 and 16
d. Add 1.5ml of ProNectin-F + PBS in to wells 5, 11 and 17
e. Incubate coated wells for 20 minutes
8. Add Cells to Wells
a. Aspirate coatings
b. Add 1ml of HUVEC media to each well
c. Add 9ml of trypsin to T-225 containing HUVECS
d. Deactivate with 27ml of HUVEC media, count sample from T-225:
i. Total of 36ml for 18 wells, 2.0ml for each well.
ii. Be extremely thorough in breaking up clumps and rinsing
e. Add 2.0ml of cell solution to each well
f. Incubate wells 6,12,18 for 5 minutes
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cells.

g. Incubate remaining wells for 15 minutes
8. Count Non-Adhered Cells in Each Well
a. Pipet all media from wells in to three new 6 well plates (make sure to label wells)
b. Take counts of non-adhered cells

A.2 6-Well Plate Coating Protocol #2
Six-Well Plate Coating Protocol
Date:
Material:
Cell Type:

.
.
.

Prep Five Days Prior
1. Prep T-75 flask for thawed cells with 20 ml of HUVEC media, allow to incubate for at least 30 min
2. Thaw 1 vial of HUVECs for T-75 flask
3. Pass cells in to T-75 flask
4. Feed cells day after thawing
5. Make sure T-225 is 80% confluent prior to set up date
Set Up Day
8. Obtain 1 six-well plate
a. Label wells 1-6

1

2

4

5

3

6

1: No Coating
2: Conditioning Media
3: ProNectin-F+HUVEC Media
4: ProNectin-F+HUVEC Media
5: HUVEC Media
6: HUVEC Media

7. Well Preparation
a. Add 1.5ml of each coating to their designated wells
b. Incubate for 20 minutes
8. Add Cells to Wells
a. Aspirate coatings
b. Add 1ml of HUVEC media to each well
c. Add 3ml of trypsin to T-75 containing HUVECs
d. Deactivate with 9ml of HUVEC media, count sample from T-75:
cells.
i. Total of 12ml for 6 wells, 2.0ml for each well.
ii. Be extremely thorough in breaking up clumps and rinsing
e. Add 2.0ml of cell solution to each well
f. Incubate wells for 5 minutes
8. Counting and Imaging Cells in Individual Wells
a. Pipet all media from wells in to a new 6 well plate (make sure to label wells)
b. Take counts of non-adhered cells
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A.3 6-Well Plate Coating Protocol #3
Six-Well Plate Coating Protocol
Date:
Material:
Cell Type:

.
.
.

Prep Five Days Prior
1. Prep T-75 flask for thawed cells with 20 ml of HUVEC media, allow to incubate for at least 30 min
2. Thaw 1 vial of HUVECs for T-75 flask
3. Pass cells in to T-75 flask
4. Feed cells day after thawing
5. Make sure T-225 is 80% confluent prior to set up date
Set Up Day
8. Obtain 1 six-well plate
a. Label wells 1-6

1

2

4

5

3

6

1: No Coating
2: Conditioning Media
3: ProNectin-F+HUVEC Media
4: ProNectin-F+HUVEC Media
5: HUVEC Media
6: HUVEC Media

7. Well Preparation
a. Add 1.5ml of each coating to their designated wells
b. Incubate for 20 minutes
8. Add Cells to Wells
a. Aspirate coatings
b. Add 1ml of HUVEC media to each well
c. Add 3ml of trypsin to T-75 containing HUVECs
d. Deactivate with 9ml of HUVEC media, count sample from T-75:
cells.
i. Total of 12ml for 6 wells, 2.0ml for each well.
ii. Be extremely thorough in breaking up clumps and rinsing
e. Add 2.0ml of cell solution to each well
f. Incubate wells for 5 minutes
8. Counting and Imaging Cells in Individual Wells
a. Pipet all media from wells in to a new 6 well plate (make sure to label wells)
b. Take counts of non-adhered cells
b. Add 1 ml of trypsin to each well
c. Deactivate trypsin with 2ml of HUVEC media in each well
d. Use 1000μL pipet to mix and break up clumps
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e. Take 20μL sample from each well for adhered cell counts

A.4 6-Well Plate Coating Protocol # 4
Six-Well Plate Coating Protocol
Date:
Material:
Cell Type:

.
.
.

Prep Five Days Prior
1. Prep T-75 flask for thawed cells with 20 ml of HUVEC media, allow to incubate for at least 30 min
2. Thaw 1 vial of HUVECs for T-75 flask
3. Pass cells in to T-75 flask
4. Feed cells day after thawing
5. Make sure T-225 is 80% confluent prior to set up date
Set Up Day
8. Obtain 1 six-well plate
a. Label wells 1-6

1

2

4

5

3

6

1: No Coating
2: Conditioning Media
3: ProNectin-F+HUVEC Media
4: ProNectin-F+HUVEC Media
5: HUVEC Media
6: HUVEC Media

7. Well Preparation
a. Add 1.5ml of each coating to their designated wells
b. Incubate for 20 minutes
8. Add Cells to Wells
a. Aspirate coatings
b. Add 1ml of HUVEC media to each well
c. Add 3ml of trypsin to T-75 containing HUVECs
d. Deactivate with 9ml of HUVEC media, count sample from T-75:
cells.
i. Total of 12ml for 6 wells, 2.0ml for each well.
ii. Be extremely thorough in breaking up clumps and rinsing
e. Add 2.0ml of cell solution to each well
f. Incubate wells for 5 minutes
8. Counting and Imaging Cells in Individual Wells
a. Pipet all media from wells in to a new 6 well plate (make sure to label wells)
b. Take counts of non-adhered cells
b. Add 1 ml of trypsin to each well
c. Deactivate trypsin with 2ml of HUVEC media in each well
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d. Centrifuge media from each well on level 4 for 4 minutes
e. Aspirate media until close to bottom of conical
f. Re-suspend cells in 0.5ml of HUVEC media
g. Take sample from each conical to count.

A.5 6-Well Plate Experiment: Varying Coating and Cell Incubations Protocol
Six-Well Plate Coating Protocol
Date:
Material:
Cell Type:

.
.
.

Prep Five Days Prior
1. Prep T-75 flask for thawed cells with 20 ml of HUVEC media, allow to incubate for at least 30 min
2. Thaw 1 vial of HUVECs for T-75 flask
3. Pass cells in to T-75 flask
4. Feed cells day after thawing
5. If T-75 is confluent, pass cells in to T-225
6. Make sure T-225 is 80% confluent prior to set up date
Set Up Day
8. Obtain 3 six-well plates
a. Label wells 1-12

1: 10 Minute Coating Incubation; 5 Minute Cell Incubation
2: 20 Minute Coating Incubations; 5 Minute Cell Incubation
3: 30 Minute Coating Incubation; 5 Minute Cell Incubation
4: 10 Minute Coating Incubation; 5 Minute Cell Incubation
5: 20 Minute Coating Incubations; 5 Minute Cell Incubation
6: 30 Minute Coating Incubation; 5 Minute Cell Incubation
7: 20 Minute Coating Incubation; 2 Minute Cell Incubation
8: 20 Minute Coating Incubation; 2 Minute Cell Incubation
9: 20 Minute Coating Incubation; 5 Minute Cell Incubation
10: 20 Minute Coating Incubation; 5 Minute Cell Incubation
11: 20 Minute Coating Incubation; 8 Minute Cell Incubation
12: 20 Minute Coating Incubation; 8 Minute Cell Incubation

7. Varying Coating Incubation Time
a. Add 1.5ml of Conditioning Media in to wells 3 and 6
b. Incubate for 10 minutes
c. Add 1.5 ml of Conditioning Media in to wells 2, 5, 7, 8, 9, 10, 11, 12.
d. Incubate for 10 minutes
e. Add 1.5ml of Conditioning Media in to wells 1 and 4
f. Incubate for 10 minutes
8. Add Cells to Wells
a. Aspirate coatings
b. Add 1ml of HUVEC media to each well
c. Add 9ml of trypsin to T-225 containing HUVECS
d. Deactivate with 27ml of HUVEC media, count sample from T-225:
i. Total of 36ml for 12 wells, 3.0ml for each well.
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cells.

ii. Be extremely thorough in breaking up clumps and rinsing
e. Add 3.0ml of cell solution to each well
f. Incubation
1. Wells 7 and 8 incubate for two minutes
2. Wells 9,10 and 1-6 incubate for five minutes
3. Wells 11 and 12 incubate for 8 minutes
8. Counting and Imaging Cells in Individual Wells
a. Pipet all media from wells in to two new 6 well plates (make sure to label wells); take counts of nonadhered cells
b. Add 1 ml of trypsin to each well as they finish cell incubation period, let sit for 5 minutes
c. Deactivate trypsin with 2ml of HUVEC media in each well
d. Centrifuge media from each well on level 4 for 4 minutes
e. Aspirate media until close to bottom of conical
f. Re-suspend cells in 0.5ml of HUVEC media
g. Take sample from each conical to count.
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A.6 6-Well Plate Experiments: Comparison Study Protocol
Six-Well Plate Coating Protocol
Date:
Material:
Cell Type:

.
.
.

Prep Five Days Prior
1. Prep T-75 flask for thawed cells with 20 ml of HUVEC media, allow to incubate for at least 30 min
2. Thaw 1 vial of HUVECs for T-75 flask
3. Pass cells in to T-75 flask
4. Feed cells day after thawing
5. If T-75 is confluent, pass cells in to T-225
6. Make sure T-225 is 80% confluent prior to set up date
Set Up Day
7. Obtain 4 six-well plates
a. Label wells 1-18

1: Conditioning Media: 60 Minute Incubation
2: Conditioning Media: 60 Minute Incubation
3: Conditioning Media: 60 Minute Incubation
4: ProNectin F: 60 Minute Incubation
5: ProNectin F: 60 Minute Incubation
6: ProNectin F: 60 Minute Incubation
7: Conditioning Media: 90 Minute Incubation
8: Conditioning Media: 90 Minute Incubation
9: Conditioning Media: 90 Minute Incubation
10: ProNectin F: 90 Minute Incubation
11: ProNectin F: 90 Minute Incubation
12: ProNectin F: 90 Minute Incubation
13: No Coating: 60 Minute Incubation
14: No Coating: 60 Minute Incubation
15: No Coating: 60 Minute Incubation
16: No Coating: 90 Minute Incubation
17: No Coating: 90 Minute Incubation
18: No Coating: 90 Minute Incubation

8. Well Preparation
a. Add 1.5ml of each coating to designated wells
b. Incubate for 20 minutes
9. Add Cells to Wells
a. Aspirate coatings
b. Add 1ml of HUVEC media to each well
c. Add 9ml of trypsin to T-225 containing HUVECS
d. Deactivate with 27ml of HUVEC media, count sample from T-225:
i. Total of 36ml for 18 wells, 2.0ml for each well.
ii. Be extremely thorough in breaking up clumps and rinsing
e. Add 2.0ml of cell solution to each well
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cells.

f. Incubation wells for designated cell incubation periods
10. Counting and Imaging Cells in Individual Wells
a. Pipet all media from wells in to two new 6 well plates (make sure to label wells); take counts of nonadhered cells
b. Add 1 ml of trypsin to each well as they finish cell incubation period, let sit for 5 minutes
c. Deactivate trypsin with 2ml of HUVEC media in each well
d. Centrifuge media from each well on level 4 for 4 minutes
e. Aspirate media until close to bottom of conical
f. Re-suspend cells in 0.5ml of HUVEC media
g. Take sample from each conical to count.
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APPENDIX B: BVM PROTOCOLS AND EXPERIMENTAL
DETAILS
B.1 Analysis of Pre-Coatings In a BVM: Protocol #1
Study Title:____________________________________
Purpose:______________________________________
Material:___________________
Diameter: __________________
Length: ____________________
Cell Type: __________________
Prep the day before
____1.

Make media:
a. Bioreactor Media (Human Complete w/o ECGS w/ antibiotics)
b. Conditioning Media (1:6 solution of FBS:M199 + antibiotics)

PLGA (1x)
____2.

Sterilize grafts 30 min 70% EtOH
i. Using syringe and cap flush luminaly and transmuraly with PBS
ii. Perform same flush procedure with Conditioning Media
____3.
Place small WM pump in hood
a. Fill coated vessel chambers with Bioreactor media (Be sure tubes are closed!)
____4.
Insert sterile grafts into biochambers. And place lid on chamber.
____5.
Using a syringe, flush lumen with Conditioning Media, ProNectin-F or PBS to prime
graft
____6.
Clamp lumen and continue to prime graft
i. Repeat for all vessels
____7.
Prime 2-port reservoirs with Conditioning Media, ProNectin-F or PBS
____8.
Attach primed biochamber to 2-port reservoir and condition graft for 20 minutes
a. Flow through lumen first to remove air, then clamp lumen and condition
transmurally on 150rpm setting
Set-up day: BVM sodding
____9.
____10.

Take corresponding number of primed biochambers and reservoirs to hood
Attach outlet of reservoir to inlet stopcock of biochamber
a. Leave reservoir inlet unattached and biochamber outlet facing trough
____11.
Record BVM numbers (or chamber ID):

____12.

Harvest cells
a. Apply Trypsin, deactivate with media
b. Take 100uL from total _____mL cells
Counts:

94

____13.

X=

x 2000 x (cell mL x .10)

total number of cells =

____14.
____15.
____16.

Pellet cell suspension (on 4 for 4 min)
Resuspend in _____mL Bioreactor Media
Sod each graft with ______mL cell solution
a. Cells per graft =
b. Sodding density =
cells/cm2
____17.
Chase with 1-3mL HUVEC Media
____18.
Attach biochamber outlet to reservoir inlet
____19.
Bring BVMs to large incubator
____20.
Place on small WM pump - leave lumen clamped!!
____21.
Immediately begin transmural flow at 10rpm, and maintain for 10 minutes
____22.
Turn off pump and allow scaffolds in incubate for 60 minutes
____23.
Harvest scaffolds from bioreactors and fix in histachoice
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B.2: Analysis of Pre-Coatings In a BVM: Protocol #2
Study Title:____________________________________
Purpose:______________________________________
Material:___________________
Diameter: __________________
Length: ____________________
Cell Type: __________________

Prep the day before
____1.

Make media:
a. Bioreactor Media (Human Complete w/o ECGS w/ antibiotics)
b. Conditioning Media (1:6 solution of FBS:M199 + antibiotics)

PLGA (1x)
____2.

Sterilize grafts 30 min 70% EtOH
i. Using syringe and cap flush luminaly and transmuraly with PBS
ii. Perform same flush procedure with Conditioning Media
____3.
Place small WM pump in hood
a. Fill coated vessel chambers with Bioreactor media PBS (Be sure tubes are closed!)
____4.
Insert sterile grafts into biochambers. And place lid on chamber.
____5.
Using a syringe, flush lumen with Conditioning Media, ProNectin-F or PBS to prime
graft
____6.
Clamp lumen and continue to prime graft
i. Repeat for all vessels
____7.
Prime 2-port reservoirs with Conditioning Media, ProNectin-F or PBS
____8.
Attach primed biochamber to 2-port reservoir and condition graft for 20 minutes
a. Flow through lumen first to remove air, then clamp lumen and condition
transmurally on 150rpm setting

Set-up day: BVM sodding
____9.
____10.

Take corresponding number of primed biochambers and reservoirs to hood
Attach outlet of reservoir to inlet stopcock of biochamber
a. Leave reservoir inlet unattached and biochamber outlet facing trough
____11.
Record BVM numbers (or chamber ID):
____12.

Harvest cells
a. Apply Trypsin, deactivate with media
b. Take 100uL from total _____mL cells
Counts:

96

____13.

X=

x 2000 x (cell mL x .10)

total number of cells =

____14.
____15.
____16.

Pellet cell suspension (on 4 for 4 min)
Resuspend in _____mL Bioreactor Media
Sod each graft with ______mL cell solution
a. Cells per graft =
b. Sodding density =
cells/cm2
____17.
Chase with 1-3mL HUVEC Media
____18.
Attach biochamber outlet to reservoir inlet
____19.
Bring BVMs to large incubator
____20.
Place on small WM pump - leave lumen clamped!!
____21.
Immediately begin transmural flow at 10rpm, and maintain for 10 minutes
____22.
Turn off pump and allow scaffolds in incubate for 60 minutes
____23.
Harvest scaffolds from bioreactors and fix in histachoice
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B.3 Proof-of-Concept Study Protocol
Study Information
Study Title:____________________________________
Purpose:______________________________________
Material:___________________
Diameter: __________________
Length: ____________________
Cell Type: __________________

Prep the day before
____1.

Make media:
a. Bioreactor Media (Human Complete w/o ECGS w/ antibiotics)
b. Conditioning Media (1:6 solution of FBS:M199 + antibiotics)

PLGA (1x)
____2.

Sterilize grafts 30 min 70% EtOH
i. Using syringe and cap flush luminaly and transmuraly with PBS
1. Repeat for non-coated scaffolds
ii. Perform same flush procedure with Conditioning Media for coated scaffolds
____3.
Place small WM pump in hood
____4.
Fill coated vessel chambers with Bioreactor media, non-coated fill with PBS (Be sure
tubes are closed!)
____5.
Insert sterile grafts into biochambers. And place lid on chamber.
____6.
Using a syringe, flush lumen with Conditioning Media, or PBS to prime graft
____7.
Clamp lumen and continue to prime graft
i. Repeat for all vessels
____8.
Prime 2-port reservoirs with Conditioning Media, or PBS
____9.
Attach primed biochamber to 2-port reservoir and condition graft for 20 minutes
a. Flow through lumen first to remove air, then clamp lumen and condition
transmurally on 150rpm setting

Set-up day: BVM sodding
____10.
____11.

Take corresponding number of primed biochambers and reservoirs to hood
Attach outlet of reservoir to inlet stopcock of biochamber
a. Leave reservoir inlet unattached and biochamber outlet facing trough
____12.
Record BVM numbers (or chamber ID):

____13.

Harvest cells
a. Apply Trypsin, deactivate with media
b. Take 100uL from total _____mL cells
Counts:

98

____14.

X=

x 2000 x (cell mL x .10)

total number of cells =

____15.
____16.
____17.

Pellet cell suspension (on 4 for 4 min)
Resuspend in _____mL HUVEC media or PBS
Sod each graft with ______mL cell solution
a. Cells per graft =
b. Sodding density =
cells/cm2
____18.
Chase with 1-3mL HUVEC Media
____19.
Attach biochamber outlet to reservoir inlet
____20.
Bring BVMs to large incubator
____21.
Place on small WM pump - leave lumen clamped!!
____22.
Immediately begin transmural flow at 10rpm, and maintain for 10 minutes
____23.
Turn off pump and allow scaffolds in incubate for 60 minutes
____24.
Harvest scaffolds from bioreactors and fix in histachoice
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B.4 Static BVM Pre-Coating Comparison Study
Study Title:____________________________________
Purpose:______________________________________
Material:___________________
Diameter: __________________
Length: ____________________
Cell Type: __________________

Prep the day before (uncoated)
____1.

Make media:
a. Bioreactor Media (Human Complete w/o ECGS w/ antibiotics)
b. Conditioning Media (1:6 solution of FBS:M199 + antibiotics)

PLGA (1x)
____2.

Sterilize grafts 30 min 70% EtOH
i. Using syringe and cap flush luminaly and transmuraly with PBS
ii. Perform same flush procedure with Conditioning Media for Conditioning
Media coated scaffolds
iii. Perform same flush procedure with ProNectin-F+HUVEC media
____3.
Place small WM pump in hood
a. Fill coated vessel chambers with Bioreactor media, ProNectin-F+HUVEC media, or
non-coated fill with PBS (Be sure tubes are closed!)
____4.
Insert sterile grafts into biochambers. And place lid on chamber.
____5.
Using a syringe, flush lumen with Conditioning Media, ProNectin-F or PBS to prime
graft
____6.
Clamp lumen and continue to prime graft
i. Repeat for all vessels
____7.
Prime 2-port reservoirs with Conditioning Media, ProNectin-F or PBS
____8.
Attach primed biochamber to 2-port reservoir and condition graft for 20 minutes
a. Flow through lumen first to remove air, then clamp lumen and condition
transmurally on 150rpm setting
Set-up day: BVM sodding
____9.
____10.

Take corresponding number of primed biochambers and reservoirs to hood
Attach outlet of reservoir to inlet stopcock of biochamber
a. Leave reservoir inlet unattached and biochamber outlet facing trough
____11.
Record BVM numbers (or chamber ID):

____12.

Harvest cells
a. Apply Trypsin, deactivate with media
b. Take 100uL from total _____mL cells
Counts:

100

____13.

X=

x 2000 x (cell mL x .10)

total number of cells =
____14.
____15.
____16.

Pellet cell suspension (on 4 for 4 min)
Resuspend in _____mL Bioreactor Media
Sod each graft with ______mL cell solution
a. Cells per graft =
b. Sodding density =
cells/cm2
____17.
Chase with 1-3mL HUVEC Media
____18.
Attach biochamber outlet to reservoir inlet
____19.
Bring BVMs to large incubator
____20.
Place on small WM pump - leave lumen clamped!!
____21.
Immediately begin transmural flow at 10rpm, and maintain for 10 minutes
____22.
Turn pump off and incubate for 60 minutes
____23.
Harvest scaffolds from bioreactors
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B.5 Dynamic BVM Pre-Coating Comparison Study
Study Title:____________________________________
Purpose:______________________________________
Material:___________________
Diameter: __________________
Length: ____________________
Cell Type: __________________

Prep the day before (uncoated)
____1.

Make media:
a. Bioreactor Media (Human Complete w/o ECGS w/ antibiotics)
b. Conditioning Media (1:6 solution of FBS:M199 + antibiotics)

PLGA (1x)
____2.

Sterilize grafts 30 min 70% EtOH
i. Using syringe and cap flush luminaly and transmuraly with PBS
ii. Perform same flush procedure with Conditioning Media for Conditioning
Media coated scaffolds
iii. Perform same flush procedure with ProNectin-F+HUVEC media
____3.
Place small WM pump in hood
____4.
Fill coated vessel chambers with Bioreactor media, ProNectin-F+HUVEC media, or
non-coated fill with PBS (Be sure tubes are closed!)
____5.
Insert sterile grafts into biochambers. And place lid on chamber.
____6.
Using a syringe, flush lumen with Conditioning Media, ProNectin-F or PBS to prime
graft
____7.
Clamp lumen and continue to prime graft
i. Repeat for all vessels
____8.
Prime 2-port reservoirs with Conditioning Media, ProNectin-F or PBS
____9.
Attach primed biochamber to 2-port reservoir and condition graft for 20 minutes
a. Flow through lumen first to remove air, then clamp lumen and condition
transmurally on 150rpm setting

Set-up day: BVM sodding
____10.
____11.

Take corresponding number of primed biochambers and reservoirs to hood
Attach outlet of reservoir to inlet stopcock of biochamber
a. Leave reservoir inlet unattached and biochamber outlet facing trough
____12.
Record BVM numbers (or chamber ID):

____13.

Harvest cells
a. Apply Trypsin, deactivate with media
b. Take 100uL from total _____mL cells
Counts:
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____14.

X=

x 2000 x (cell mL x .10)

total number of cells =

____15.
____16.
____17.

Pellet cell suspension (on 4 for 4 min)
Resuspend in _____mL Bioreactor Media
Sod each graft with ______mL cell solution
a. Cells per graft =
b. Sodding density =
cells/cm2
____18.
Chase with 1-3mL HUVEC Media
____19.
Attach biochamber outlet to reservoir inlet
____20.
Bring BVMs to large incubator
____21.
Place on small WM pump - leave lumen clamped!!
____22.
Immediately begin transmural flow at 10rpm, and maintain for 1 hour
a. Started on pump at: ______ (time)
____23.
Unclamp lumen and maintain 10rpm luminal flow for 1 hour
____24.
Increase flow by 10-15rpm each hour at a time to reach 90rpm by the end of the day
____25.
Harvest scaffolds from bioreactors
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APPENDIX C: STAINING PROTOCOLS AND EXPERIMENTAL
DETAILS
C.1 BBI Staining Protocol
1. Wrap nonsterile 15-mL conicals in foil. Thoroughly label conicals for all samples.
2. Make BBI solution. Always keep stock solution wrapped in foil!
a. Use small tube of stock solution and dilute 1:1000 with milli-Q water (10 L stock
solution in 10 mL water). Use pipette aid from room 209 hood for milli-Q water;
spray pipette aid before placing back in hood.
b. Mix by inverting.
3. Put on safety glasses. Cut samples with blade or scissors, being careful to not disrupt cell lining
inside lumen (squeezing, touching, and scraping can all disrupt lining and ruin experiment).
4. Use washed forceps to place samples in corresponding 15-mL conicals that contain BBI
solution. Carefully keep track of samples. Leave foil on conicals.
a. Let samples soak for at least 15 minutes (longer is better).
5. Put away extra stock solution. Clean up preparation area.
6. With permission or help from Dr. Cardinal, use fluorescent microscope to obtain en face
images. Take forceps to use at microscope.
a.
b.
c.
d.
e.
f.
g.
h.
i.
j.
k.
l.
m.
n.
o.
p.
q.
r.
s.
t.

u.

Log into notebook (fluorescence; initials; date; time and lamp hours).
Turn turret to setting 4.
Turn on Olympus lamp (green switch).
Turn on Optiscan wheels (black switch).
Turn on camera (black switch).
Set filter wheel 1 to 1, and set filter wheel 2 to 1.
Open shutter:
Set Prior keypad to shutter S1.
Dial objectives to desired magnification (typically 4x and 10x for BBI images).
Set thin bar to icon of eye and camera.
Sign into computer by clicking Kristen’s account (password can be obtained from
Kristen).
Click QCapture Pro (on desktop).
Click camera icon at top of QCapture Pro window:
Place slide on microscope. Place sample on slide.
See image.
Manually adjust microscope to clarify image.
If scaffold is too wet, carefully blot end of scaffold on Kim wipe.
Take pictures. Save pictures if desired (labeled with sample info, initials, and
magnification).
Quit QCapture Pro. Log out of computer.
Shut down microscope by switching off Olympus lamp, switching off Optiscan
wheels, switching off camera (on top of microscope), closing shutter, and setting thin
bar to icon of eye.
Log out of notebook.
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e

j

a, t
g
d
c
b
i
p
f, h

a. Click “More”.

b. Click “Preview”.
c. Click setting 1.
d. Click “Auto Set”. If
“White Balance” window
pops up, close it.
e. Type larger number
in mmm blank for
lighter image and
smaller number for
darker image.
f. Click + to increase
size of image window
and – to decrease size
of image window.
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C.2 Rhodamine phalloidin Staining Protocol
1. Wash cells twice with prewarmed phosphate-buffered saline, pH 7.4 (PBS).
2. Fix the sample in 3.7% formaldehyde solution in PBS for 10 minutes at room
temperature. Note: Methanol can disrupt actin during the fixation process. Therefore, it is
best to avoid any methanol containing fixatives. The preferred fixative is methanol-free
formaldehyde.
3. Wash two or more times with PBS.
4. Place each coverslip in a glass petri dish and extract it with a solution of acetone at =–
20°C or 0.1% Triton X-100 in PBS for 3 to 5 minutes.
5. Wash two or more times with PBS.
6. When staining with any of the fluorescent phallotoxins, dilute 5 µL methanolic stock
solution into 200 µL PBS for each coverslip to be stained. To reduce nonspecific
background staining with these conjugates, add 1% bovine serum albumin (BSA) to the
staining solution. It may also be useful to pre-incubate fixed cells with PBS containing
1% BSA or with the Image-iT™ FX signal enhancer (I36933) for 20–30 minutes prior to
adding the phallotoxin staining solution. When staining with biotin-XX phalloidin
(B7474), dilute 10 µL of the methanolic stock solution into 200 µL PBS for each
coverslip to be stained. When staining more than one coverslip, adjust volumes
accordingly. For a stronger signal, use 2 or 3 units per coverslip.
7. Place the staining solution on the coverslip for 20 minutes at room temperature
(generally, any temperature between 4°C and 37°C is suitable). To avoid evaporation,
keep the coverslips inside a covered container during the incubation.
8. Wash two or more times with PBS.
9. When using biotin-XX phalloidin, incubate for 30 minutes with 100 µL of a 10 µg/mL
solution of fluorescent or enzyme-conjugated streptavidin dissolved in 100 mM Tris-HCl,
pH 7.5, 150 mM NaCl, 0.3% Triton X-100 and 1% BSA. Incubate for 15 minutes at room
temperature. After incubation, wash the coverslip with PBS. To develop enzyme activity,
follow a procedure recommended for the specific enzyme.
10. For long-term storage, the cells should be air dried and then mounted in a permanent
mountant such as ProLong® Gold reagent or Cytoseal. Specimens prepared in this
manner retain actin staining for at least six months when stored in the dark at 2–6°C.
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